UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~March 31,~~June 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _______

COMMISSION FILE NUMBER 001-38661

Elanco Animal Health Incorporated

(Exact name of Registrant as specified in its charter)


INDIANA						82-5497352
(State or other jurisdiction of						(I.R.S. Employer
incorporation or organization)						Identification No.)

2500 INNOVATION WAY, GREENFIELD, INDIANA 46140

(Address and zip code of principal executive offices)

Registrant’s telephone number, including area code (877) 352-6261

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, no par value	ELAN	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares of common stock outstanding as of ~~May 4,~~August 3, 2023 was ~~492,550,481.~~492,675,580.

ELANCO ANIMAL HEALTH INCORPORATED

FORM 10-Q

FOR THE QUARTER ENDED ~~MARCH 31,~~JUNE 30, 2023

TABLE OF CONTENTS

PART 1. Financial Information

Item 1.

FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (L OSS ) (UNAUDITED)

CONDENSED CONSOLIDATED BALANCE SHEETS

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

2420

RESULTS OF OPERATIONS

2821

SUMMARY OF CHANGES

3024

LIQUIDITY AND CAPITAL RESOURCES

3226

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

3428

Item 4.

CONTROLS AND PROCEDURES

3528

PART II. Other Information

Item 1.

Item 1A.

Item 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

3730

Item 3.

DEFAULTS UPON SENIOR SECURITIES

3730

Item 4.

MINE SAFETY DISCLOSURES

Item 5.

Item 6.


			2023 Q1Q2 Form 10-Q \| 1

~~Table~~Ta le of Contents

FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

This Quarterly Report on Form 10-Q (Form 10-Q) includes forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements concerning the impact on Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us or our) caused by the integration of business acquisitions, expected synergies and cost savings, product launches, global macroeconomic conditions, expectations relating to liquidity and sources of capital, our expected compliance with debt covenants, cost savings, expenses and reserves relating to restructuring actions, our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following:

•heightened competition, including from generics;

•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;

•changes in regulatory restrictions on the use of antibiotics in farm animals;

•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;

•consolidation of our customers and distributors;

•an outbreak of infectious disease carried by farm animals;

•demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern;

•the potential impact on our business and global economic conditions resulting from the conflict involving Russia and Ukraine;

•the success of our research and development (R&D) and licensing efforts;

•misuse, off-label or counterfeiting use of our products;

•unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;

•fluctuations in our business results due to seasonality and other factors;

•the impact of weather conditions, including those related to climate change, and the availability of natural resources;

•risks related to the modification of foreign trade policy;

•risks related to currency exchange rate fluctuations;

•our dependence on the success of our top products;

•the impact of customer exposure to rising costs and reduced customer income;

•the lack of availability or significant increases in the cost of raw materials;

•the impact of increased or decreased sales into our distribution channels resulting in ~~fluctuation~~fluctuations in our revenues;

•risks related to the write-down of goodwill or identifiable intangible assets;

•risks related to the evaluation of animals;

•manufacturing problems and capacity imbalances;


			~~2023 Q1 Form 10-Q \|~~ 2

~~Table of Contents~~

•the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters;


			2023 Q2 Form 10-Q \| 2

Ta le of Contents

•actions by regulatory bodies, including as a result of their interpretation of studies on product safety;

•risks related to tax expense or exposure;

•risks related to environmental, health and safety laws and regulations;

•risks related to our presence in foreign markets;

•challenges to our intellectual property rights or our alleged violation of rights of others;

•our dependence on sophisticated information technology and infrastructure and the impact of breaches of our information technology systems;

•the impact of increased regulation or decreased financial support related to farm animals;

•adverse effects of labor disputes, strikes, work stoppages and the loss of key personnel or highly skilled employees;

•risks related to underfunded pension plan liabilities;

•our ability to complete acquisitions and successfully integrate the businesses we acquire, including Kindred Biosciences, Inc. (KindredBio) and the animal health business of Bayer Aktiengesellschaft (Bayer Animal Health) ~~and specifically the impact of the integration of ERP systems in April 2023 and related sales order processing blackout periods and their impact on revenue in the second quarter of 2023;~~;

•the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that ~~will~~ limit our operating ~~flexibility;~~flexibility, and changes in our credit ratings that lead to higher borrowing expenses;

•risks related to certain governance provisions in our constituent documents; and

•any failure to maintain an effective system of disclosure controls and internal control over financial reporting, including arising from an identified material weakness.

See Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the United States (U.S.) Securities and Exchange Commission (SEC) (2022 Form 10-K), and Part II of this Form 10-Q, for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this quarterly report. Any forward-looking statement made by us in this quarterly report speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.


			2023 Q1Q2 Form 10-Q \| 3

~~Table~~Ta le of Contents

PART I

ITEM 1. FINANCIAL STATEMENTS

Elanco Animal Health Incorporated

Condensed Consolidated Statements of Operations (Unaudited)

(in millions, except per-share data)


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022				2023		2022		2023		2022
Revenue	Revenue	$	1,257	$	1,226		Revenue	$	1,057	$	1,175	$	2,314	$	2,401
Costs, expenses and other:	Costs, expenses and other:						Costs, expenses and other:
Cost of sales	Cost of sales	494		509			Cost of sales	434		484		928		993
Research and development	Research and development	81		81			Research and development	81		82		162		163
Marketing, selling and administrative	Marketing, selling and administrative	327		323			Marketing, selling and administrative	353		343		680		666
Amortization of intangible assets	Amortization of intangible assets	134		137			Amortization of intangible assets	136		133		270		270
Asset impairment, restructuring and other special charges	Asset impairment, restructuring and other special charges	40		40			Asset impairment, restructuring and other special charges	35		86		75		126
Interest expense, net of capitalized interest	Interest expense, net of capitalized interest	64		52			Interest expense, net of capitalized interest	74		67		138		119
Other expense, net		9		9
Other expense (income), net							Other expense (income), net	23		(6)		32		3
		1,149		1,151				1,136		1,189		2,285		2,340
Income before income taxes		108		75
Income tax expense		5		24
Net income		$	103	$	51
(Loss) income before income taxes							(Loss) income before income taxes	(79)		(14)		29		61
Income tax expense (benefit)							Income tax expense (benefit)	18		(4)		23		20
Net (loss) income							Net (loss) income	$	(97)	$	(10)	$	6	$	41

Earnings per share:
(Loss) earnings per share:							(Loss) earnings per share:
Basic	Basic	$	0.21	$	0.10		Basic	$	(0.20)	$	(0.02)	$	0.01	$	0.08
Diluted	Diluted	$	0.21	$	0.10		Diluted	$	(0.20)	$	(0.02)	$	0.01	$	0.08
Weighted average shares outstanding:	Weighted average shares outstanding:						Weighted average shares outstanding:
Basic	Basic	491.1		488.0			Basic	492.6		488.4		491.8		488.2
Diluted	Diluted	492.8		492.2			Diluted	492.6		488.4		492.7		492.1

See accompanying notes to condensed consolidated financial statements.


			2023 Q1Q2 Form 10-Q \| 4

~~Table~~Ta le of Contents

Elanco Animal Health Incorporated

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

(in millions)
Three Months Ended March 31,
2023 2022
Net income $ 103 $ 51
Other comprehensive income (loss):
Cash flow hedges, net of taxes (48) 109
Foreign currency translation 130 (85)
Defined benefit pension and retiree health benefit plans, net of taxes — (1)
Other comprehensive income, net of taxes 82 23
Comprehensive income $ 185 $ 74


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Net (loss) income	$	(97)	$	(10)	$	6	$	41
Other comprehensive income (loss):
Cash flow hedges, net of taxes	29		8		(19)		117
Foreign currency translation, net of taxes	2		(470)		132		(555)
Defined benefit pension and retiree health benefit plans, net of taxes	(2)		(1)		(2)		(2)
Other comprehensive income (loss), net of taxes	29		(463)		111		(440)
Comprehensive (loss) income	$	(68)	$	(473)	$	117	$	(399)

See accompanying notes to condensed consolidated financial statements.


			2023 Q1Q2 Form 10-Q \| 5

~~Table~~Ta le of Contents

Elanco Animal Health Incorporated

Condensed Consolidated Balance Sheets

(in millions, except share data)


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
		(Unaudited)					(Unaudited)
Assets	Assets					Assets
Current Assets	Current Assets					Current Assets
Cash and cash equivalents	Cash and cash equivalents	$	318	$	345	Cash and cash equivalents	$	367	$	345
Accounts receivable, net of allowances of $15 (2023) and $13 (2022)		1,051		797
Accounts receivable, net						Accounts receivable, net	1,000		797
Other receivables	Other receivables	213		205		Other receivables	225		205
Inventories	Inventories	1,596		1,538		Inventories	1,690		1,538
Prepaid expenses and other	Prepaid expenses and other	370		394		Prepaid expenses and other	370		394

Total current assets	Total current assets	3,548		3,279		Total current assets	3,652		3,279
Noncurrent Assets	Noncurrent Assets					Noncurrent Assets

Goodwill	Goodwill	6,061		5,993		Goodwill	6,040		5,993
Other intangibles, net	Other intangibles, net	4,791		4,842		Other intangibles, net	4,678		4,842
Other noncurrent assets	Other noncurrent assets	369		378		Other noncurrent assets	419		378
Property and equipment, net of accumulated depreciation of $744 (2023) and $723 (2022)		1,000		999
Property and equipment, net						Property and equipment, net	1,007		999

Total assets	Total assets	$	15,769	$	15,491	Total assets	$	15,796	$	15,491
Liabilities and Equity	Liabilities and Equity					Liabilities and Equity
Current Liabilities	Current Liabilities					Current Liabilities
Accounts payable	Accounts payable	$	381	$	390	Accounts payable	$	354	$	390
Employee compensation		110		146
Sales rebates and discounts	Sales rebates and discounts	329		324		Sales rebates and discounts	332		324
Current portion of long-term debt	Current portion of long-term debt	381		388		Current portion of long-term debt	39		388

Other current liabilities	Other current liabilities	377		454		Other current liabilities	559		600

Total current liabilities	Total current liabilities	1,578		1,702		Total current liabilities	1,284		1,702
Noncurrent Liabilities	Noncurrent Liabilities					Noncurrent Liabilities
Long-term debt	Long-term debt	5,639		5,448		Long-term debt	6,023		5,448
Accrued retirement benefits		164		161

Deferred taxes	Deferred taxes	663		662		Deferred taxes	658		662
Other noncurrent liabilities	Other noncurrent liabilities	245		229		Other noncurrent liabilities	411		390
Total liabilities	Total liabilities	8,289		8,202		Total liabilities	8,376		8,202
Commitments and Contingencies	Commitments and Contingencies					Commitments and Contingencies
Equity	Equity					Equity

Preferred stock, no par value, 1,000,000,000 shares authorized; none issued		—		—
Common stock, no par value, 5,000,000,000 shares authorized, 492,418,216 and 474,237,738 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		—		—

Common stock, no par value, 5,000,000,000 shares authorized, 492,554,242 and 474,237,738 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively						Common stock, no par value, 5,000,000,000 shares authorized, 492,554,242 and 474,237,738 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	—		—
Additional paid-in capital	Additional paid-in capital	8,744		8,738		Additional paid-in capital	8,752		8,738
Accumulated deficit	Accumulated deficit	(954)		(1,057)		Accumulated deficit	(1,051)		(1,057)
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(310)		(392)		Accumulated other comprehensive loss	(281)		(392)
Total equity	Total equity	7,480		7,289		Total equity	7,420		7,289
Total liabilities and equity	Total liabilities and equity	$	15,769	$	15,491	Total liabilities and equity	$	15,796	$	15,491

See accompanying notes to condensed consolidated financial statements.


			2023 Q1Q2 Form 10-Q \| 6

~~Table~~Ta le of Contents

Elanco Animal Health Incorporated

Condensed Consolidated Statements of Equity (Unaudited)

(Dollars and shares in millions)


		Common Stock							Accumulated Other Comprehensive Loss											Common Stock							Accumulated Other Comprehensive Loss
		Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Cash Flow Hedge		Foreign Currency Translation		Defined Benefit Pension and Retiree Health Benefit Plans		Total		Total Equity			Shares	Amount		Additional Paid-in Capital		Accumulated Deficit		Cash Flow Hedge		Foreign Currency Translation		Defined Benefit Pension and Retiree Health Benefit Plans		Total		Total Equity
December 31, 2021	December 31, 2021	473.1	$	—	$	8,696	$	(979)	$	25	$	(253)	$	19	$	(209)	$	7,508	December 31, 2021	473.1	$	—	$	8,696	$	(979)	$	25	$	(253)	$	19	$	(209)	$	7,508

Net income	Net income	—	—		—		51		—		—		—		—		51		Net income	—	—		—		51		—		—		—		—		51

Other comprehensive income (loss), net of tax	Other comprehensive income (loss), net of tax	—	—		—		—		109		(85)		(1)		23		23		Other comprehensive income (loss), net of tax	—	—		—		—		109		(85)		(1)		23		23

Stock-based compensation		—	—		14		—		—		—		—		—		14
Issuance of stock under employee stock plans, net		1.0	—		(11)		—		—		—		—		—		(11)
Stock-based compensation activity, net																			Stock-based compensation activity, net	1.0	—		3		—		—		—		—		—		3

March 31, 2022	March 31, 2022	474.1	$	—	$	8,699	$	(928)	$	134	$	(338)	$	18	$	(186)	$	7,585	March 31, 2022	474.1	—		8,699		(928)		134		(338)		18		(186)		7,585
Net loss																			Net loss	—	—		—		(10)		—		—		—		—		(10)
Other comprehensive income (loss), net of tax																			Other comprehensive income (loss), net of tax	—	—		—		—		8		(470)		(1)		(463)		(463)
Stock-based compensation activity, net																			Stock-based compensation activity, net	—	—		13		—		—		—		—		—		13

June 30, 2022																			June 30, 2022	474.1	$	—	$	8,712	$	(938)	$	142	$	(808)	$	17	$	(649)	$	7,125


December 31, 2022	December 31, 2022	474.2	$	—	$	8,738	$	(1,057)	$	182	$	(672)	$	98	$	(392)	$	7,289	December 31, 2022	474.2	$	—	$	8,738	$	(1,057)	$	182	$	(672)	$	98	$	(392)	$	7,289

Net income	Net income	—	—		—		103		—		—		—		—		103		Net income	—	—		—		103		—		—		—		—		103
Other comprehensive income (loss), net of tax	Other comprehensive income (loss), net of tax	—	—		—		—		(48)		130		—		82		82		Other comprehensive income (loss), net of tax	—	—		—		—		(48)		130		—		82		82

Stock-based compensation		—	—		11		—		—		—		—		—		11
Issuance of stock under employee stock plans, net		0.9	—		(6)		—		—		—		—		—		(6)
Issuance of stock under employee stock purchase plan, net		0.1	—		1		—		—		—		—		—		1
Stock-based compensation activity, net																			Stock-based compensation activity, net	1.0	—		6		—		—		—		—		—		6

Conversion of tangible equity units (TEUs) into common stock	Conversion of tangible equity units (TEUs) into common stock	17.2	—		—		—		—		—		—		—		—		Conversion of tangible equity units (TEUs) into common stock	17.2	—		—		—		—		—		—		—		—

March 31, 2023	March 31, 2023	492.4	$	—	$	8,744	$	(954)	$	134	$	(542)	$	98	$	(310)	$	7,480	March 31, 2023	492.4	—		8,744		(954)		134		(542)		98		(310)		7,480
Net loss																			Net loss	—	—		—		(97)		—		—		—		—		(97)
Other comprehensive income (loss), net of tax																			Other comprehensive income (loss), net of tax	—	—		—		—		29		2		(2)		29		29
Stock-based compensation activity, net																			Stock-based compensation activity, net	0.2	—		8		—		—		—		—		—		8

June 30, 2023																			June 30, 2023	492.6	$	—	$	8,752	$	(1,051)	$	163	$	(540)	$	96	$	(281)	$	7,420

See accompanying notes to condensed consolidated financial statements.


			2023 Q1Q2 Form 10-Q \| 7

~~Table~~Ta le of Contents

Elanco Animal Health Incorporated

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in millions)


		Three Months Ended March 31,					Six Months Ended June 30,
		2023		2022			2023		2022
Cash Flows from Operating Activities	Cash Flows from Operating Activities					Cash Flows from Operating Activities
Net income	Net income	$	103	$	51	Net income	$	6	$	41
Adjustments to reconcile net income to cash flows from operating activities:	Adjustments to reconcile net income to cash flows from operating activities:					Adjustments to reconcile net income to cash flows from operating activities:
Depreciation and amortization	Depreciation and amortization	173		176		Depreciation and amortization	350		347
Deferred income taxes		2		(7)

Stock-based compensation expense	Stock-based compensation expense	12		14		Stock-based compensation expense	21		31
Asset impairment and write-down charges	Asset impairment and write-down charges	—		22		Asset impairment and write-down charges	—		81
Loss on sale of assets		1		1

Inventory fair value step-up amortization		1		—

Proceeds from interest rate swap settlements						Proceeds from interest rate swap settlements	—		132

Changes in operating assets and liabilities, net of acquisitions	Changes in operating assets and liabilities, net of acquisitions	(439)		(332)		Changes in operating assets and liabilities, net of acquisitions	(473)		(384)

Other non-cash operating activities, net	Other non-cash operating activities, net	2		13		Other non-cash operating activities, net	12		2
Net Cash Used for Operating Activities		(145)		(62)
Net Cash (Used for) Provided by Operating Activities						Net Cash (Used for) Provided by Operating Activities	(84)		250
Cash Flows from Investing Activities	Cash Flows from Investing Activities					Cash Flows from Investing Activities

Net purchases of property and equipment		(20)		(19)
Net purchases of property and equipment and software						Net purchases of property and equipment and software	(66)		(58)
Cash paid for acquisitions	Cash paid for acquisitions	(16)		—		Cash paid for acquisitions	(16)		—

Purchases of intangible assets	Purchases of intangible assets	(14)		—		Purchases of intangible assets	(14)		(1)
Purchases of software		(4)		(7)

Other investing activities, net	Other investing activities, net	(1)		(3)		Other investing activities, net	(2)		(7)
Net Cash Used for Investing Activities	Net Cash Used for Investing Activities	(55)		(29)		Net Cash Used for Investing Activities	(98)		(66)
Cash Flows from Financing Activities	Cash Flows from Financing Activities					Cash Flows from Financing Activities

Proceeds from issuance of long-term debt						Proceeds from issuance of long-term debt	—		425
Proceeds from revolving credit facility	Proceeds from revolving credit facility	200		63		Proceeds from revolving credit facility	250		563

Repayments of long-term borrowings	Repayments of long-term borrowings	(19)		(89)		Repayments of long-term borrowings	(32)		(528)
Repayments of revolving credit facility	Repayments of revolving credit facility	—		(163)		Repayments of revolving credit facility	—		(738)

Other financing activities, net	Other financing activities, net	(7)		(11)		Other financing activities, net	(5)		(17)
Net Cash Provided by (Used for) Financing Activities	Net Cash Provided by (Used for) Financing Activities	174		(200)		Net Cash Provided by (Used for) Financing Activities	213		(296)
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(1)		(5)		Effect of exchange rate changes on cash and cash equivalents	(9)		(19)
Net decrease in cash and cash equivalents		(27)		(296)
Cash and cash equivalents at January 1		345		638
Cash and cash equivalents at March 31		$	318	$	342
Net increase (decrease) in cash and cash equivalents						Net increase (decrease) in cash and cash equivalents	22		(131)
Cash and cash equivalents – beginning of period						Cash and cash equivalents – beginning of period	345		638
Cash and cash equivalents – end of period						Cash and cash equivalents – end of period	$	367	$	507

See accompanying notes to condensed consolidated financial statements.


			2023 Q1Q2 Form 10-Q \| 8

~~Table~~Ta le of Contents

Elanco Animal Health Incorporated

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Tables present dollars and shares in millions, except per-share and per-unit data)

~~Note 1. Background~~

Elanco is a global animal health company that innovates, develops, manufactures and markets products for pets and farm animals. We offer a portfolio of approximately 200 brands to pet owners, veterinarians and farm animal producers in more than 90 countries. Our products are generally sold worldwide directly to wholesalers, distributors and independent retailers. Certain products are also sold directly to farm animal producers and veterinarians. We have a diversified business of products across species consisting of: dogs and cats (collectively, pet health) and cattle, poultry, swine and aqua (collectively, farm animal).

~~Elanco was incorporated in Indiana on September 18, 2018, and prior to that was a business unit of Eli Lilly and Company (Lilly).~~

Note 2.1. Basis of Presentation and Summary of Significant Accounting Policies

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the SEC requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in our 2022 Form 10-K. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2023 or any other future period.

In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. Certain reclassifications of prior year information have been made to conform to the current year's presentation.

The significant accounting policies set forth in Note 4 to the consolidated financial statements in our 2022 Form 10-K appropriately represent, in all material respects, the current status of our accounting policies.

Revision of Previously Issued Consolidated Financial Statements

In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified and corrected relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. In conjunction with making these corrections, we made other adjustments to the prior years to revise uncorrected errors. The appropriate revisions to our historical condensed consolidated financial statements and the notes thereto are reflected herein. Further information is included in Note 2 and Note 21 to the consolidated financial statements in our 2022 Form 10-K.


			~~2023 Q1 Form 10-Q \|~~ 9

~~Table of Contents~~

Note 3.2. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of an accounting standard that was recently adopted:

Standard

Description

Effective Date

Effect on the Financial Statements or Other Significant Matters

ASU 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope; ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848

ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions. ASU 2022-06 extends the period of time entities can utilize the reference rate reform relief guidance under ASU 2020-04 from December 31, 2022 to December 31, 2024.

Adoption of the guidance is optional and effective as of March 12, 2020 through December 31, 2024. Adoption is permitted at any time during the period on a prospective basis.

Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we have transitioned the reference rate used in our credit facilities from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (Term SOFR). The change did not have a material impact on our condensed consolidated financial statements.

~~Note 4. Revenue~~

Our sales rebates and discounts are based on specific agreements. The most significant of our sales rebate and discount programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of March 31, 2023 and 2022, the aggregate liability for sales rebates and discounts for these countries represented approximately 76% and 74%, respectively, of our total liability.

~~The following table summarizes the activity in our global sales rebates and discounts liability:~~
Three Months Ended March 31,
2023 2022
Beginning balance $ 324 $ 319
Reduction of revenue 209 219
Payments (204) (241)
Ending balance $ 329 $ 297

~~Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three months endedMarch 31, 2023 and 2022 for product shipped in previous periods were not material.~~

~~Actual global product returns were less than 1% of net revenue for the three months ended March 31, 2023 and 2022.~~


			2023 Q1Q2 Form 10-Q \| 109

~~Table~~Ta le of Contents

Note 3. Revenue

We recognize revenue primarily from product sales to customers. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligations, which is generally once the goods have been shipped and the customer has assumed title. For contract manufacturing organization (CMO) arrangements, we recognize revenue over time or at a point in time depending on our evaluation of when the customer obtains control of the promised goods or services.

We have a single customer that accounted for approximately 9% and 10% of revenue for the six months ended June 30, 2023 and 2022, respectively. Product sales with this customer resulted in accounts receivable of $84 million and $73 million as of June 30, 2023 and December 31, 2022, respectively.

Provisions for sales rebates and discounts are established in the same period the related sales are recognized and are based on specific agreements. Sales rebates and discounts are recorded as a reduction to revenue. In determining the appropriate accrual amount, we consider our historical experience with similar incentive programs, current sales data and estimates of inventory levels at our channel distributors. The following table summarizes the activity in our global sales rebates and discounts liability:


	Six Months Ended June 30,
		2023		2022
Beginning balance		$	324	$	316

Reduction of revenue		387		355
Payments		(379)		(387)

Ending balance		$	332	$	284

Adjustments to revenue recognized as a result of changes in estimates during the six months endedJune 30, 2023 and 2022 for product shipped in previous periods were not material. Actual global product returns were approximately 1% of net revenue for the six months ended June 30, 2023 and 2022.

Disaggregation of Revenue

The following table summarizes our revenue disaggregated by product category:


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
		2023		2022				2023		2022		2023		2022
Pet Health	Pet Health	$	675	$	640		Pet Health	$	518	$	610	$	1,193	$	1,250
Farm Animal:	Farm Animal:						Farm Animal:
Cattle	Cattle	248		247			Cattle	210		248		458		495
Poultry	Poultry	183		180			Poultry	178		174		361		353
Swine	Swine	102		99			Swine	89		89		191		189
Aqua	Aqua	40		43			Aqua	50		42		90		85
Total Farm Animal	Total Farm Animal	573		569			Total Farm Animal	527		553		1,100		1,122
Contract Manufacturing (1)	Contract Manufacturing (1)	9		17			Contract Manufacturing (1)	12		12		21		29
Revenue	Revenue	$	1,257	$	1,226		Revenue	$	1,057	$	1,175	$	2,314	$	2,401

(1)Represents revenue from arrangements in which we manufacture products on behalf of a third party.

The following table summarizes our revenue disaggregated by geographic area:


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022

United States	$	500	$	539	$	1,043	$	1,061
International	557		636		1,271		1,340


Revenue	$	1,057	$	1,175	$	2,314	$	2,401

Note 5.4. Acquisitions, Divestitures and Other Arrangements

NutriQuest U.S. Acquisition

On January 3, 2023, we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest). NutriQuest is a provider of swine, poultry and cattle nutritional health products to animal producers. The acquisition allows us to expand our existing nutritional health offerings and furthers our efforts to explore innovative antibiotic alternatives.


			2023 Q2 Form 10-Q \| 10

Ta le of Contents

The composition of the purchase price iswas as follows:


Up-front cash consideration	$	16
Deferred cash consideration due January 4, 2024	5
Fair value of contingent consideration	3537
Total purchase consideration	$	5658

Contingent consideration includes up to $85 million of cash consideration payable if specific development, sales and geographic expansion milestones are achieved. We recorded a $35 million liability on the condensed consolidated balance sheet as of theThe NutriQuest acquisition ~~date based on the fair value of the contingent consideration. See Note 10: Financial Instruments and Fair Value for further information.~~

~~The transaction~~ was accounted for as a business combination under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired assets has been recorded as goodwill. Contingent consideration includes up to $85 million of cash consideration payable if specific development, sales and geographic expansion milestones are achieved, as outlined in the asset purchase agreement. The ~~results~~initial fair value assessment of ~~operations~~this contingent consideration liability of $37 million was estimated as of the acquisition ~~are included in our condensed consolidated financial statements from~~date using a Monte Carlo simulation model, which represented a Level 3 measurement under the ~~date of acquisition.~~

~~Revenue and income from NutriQuest included in our condensed consolidated statements of operations~~fair value measurement hierarchy (see Note 10. Fair Value for ~~the three months ended March 31, 2023 were immaterial.~~


			~~2023 Q1 Form 10-Q \|~~ 11

~~Table of Contents~~

further information).

The following table summarizes the preliminary amounts recognized for assets acquired as of the acquisition date:


~~Estimated Fair Value at January 3, 2023~~
Inventory	$	3
Intangible assets:
Marketed products	2829
Acquired in-process research and development (IPR&D)	910
Other intangible assets	15

Total identifiable assets	5557
Goodwill~~(1)~~	1
Total consideration transferred	$	5658

~~(1)~~The goodwill recognized from this acquisition is primarily attributable to NutriQuest's assembled workforce and expected synergies. The goodwill associated with this acquisition is deductible for tax purposes.

Other intangible assets consist of customer relationships and trade names. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 12 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk and competitive trends impacting the asset and each cash flow stream, as well as other factors.

The accounting for this acquisition has not been finalized as of ~~March 31,~~June 30, 2023. The purchase price allocation is preliminary and subject to change, including the valuation of the contingent consideration and intangible assets. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date.

~~Pending Acquisition~~

Revenue attributable to the NutriQuest acquisition for the six months ended June 30, 2023, was approximately $9 million.

NutriQuest Brazil

Acquisition

On ~~January 22,~~August 1, 2023, we ~~entered into an asset purchase agreement to acquire~~acquired certain assets including inventory and distribution rights for certain marketed products ~~and certain other assets of~~from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil). ~~Pursuant~~As of the closing date, we paid cash consideration of approximately $3 million, with future payments required through 2026 of up to $19 million, pursuant to the terms and conditions set forth in the asset purchase ~~agreement, total consideration is $24 million to be paid in two installments, subject to certain post-closing adjustments.~~agreement. The ~~transaction is expected to close within~~accounting for this acquisition was incomplete at the ~~next six months. We~~time the condensed consolidated financial statements were issued; however, we anticipate ~~that~~ this transaction will be accounted for as a business combination under the acquisition method of accounting.


			~~2023 Q1 Form 10-Q \|~~ 12

~~Table of Contents~~

Divestitures

Microbiome R&D platform carve-out

In April 2022, we signed an agreement to transfer assets associated with our microbiome R&D platform to a newly created, independent biopharmaceutical company, BiomEdit, focused on developing solutions for animal and human health. As part of the agreement, we retained a non-voting, minority stake in the company. In addition, we entered into transitional services agreements with the company for certain services. Assets transferred included


			2023 Q2 Form 10-Q \| 11

Ta le of Contents

intellectual property and laboratory equipment. The book values of those assets were not material. We recorded a gain on disposal of the assets of approximately $3 million during the year ended December 31, 2022. We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results. During the three months ended March 31, 2023, we recorded an immaterial gain in other expense, net in our condensed consolidated statements of operations in connection with the sale of additional equity by BiomEdit.

Shawnee and Speke

During 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee, Kansas (Shawnee) and Speke, U.K. (Speke), including the transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx began manufacturing existing Elanco products at both sites upon the closing of the transactions. On August 1, 2021 and February 1, 2022, we completed the sales of our Shawnee and Speke sites, respectively. Upon closing the sale of the Speke site, we recorded a contract asset of $55 million for the favorable supply agreement, which iswas included in prepaid expenses and other and other noncurrent assets on our condensed consolidated balance sheets. Our fair value assessment for the favorable supply agreement was estimated using a combined income and market approach which incorporated Level 3 inputs. The divestitures did not represent a strategic shift that has or will have a major effect on our operations and financial results, and therefore do not qualify for reporting as discontinued operations. See Note 6: Asset Impairment, Restructuring and Other Special Charges for further information.

Based on the terms of the agreements ~~we expect to receive aggregate gross~~and cash proceeds received to date, as of ~~$78~~June 30, 2023, we had a net receivable balance from TriRx of $71 million from the sales of Shawnee and Speke, ~~over a period~~ of ~~three years~~ which ~~began~~$65 million was included within other receivables on the condensed consolidated balance sheets, with the remainder included in ~~the second half of 2022. Through March 31, 2023, we have received cash proceeds totaling $13 million.~~other noncurrent assets. In May 2023, we entered into amendments to the agreements which effectively restructured the payment schedule related to the remaining amount owed. Under the terms of the amendments, we expect to receive the ~~remaining cash proceeds~~$65 million current portion of this receivable balance upon the earlier of the date on which certain conditions are met or in equal installments over a twelve-month period beginning January 31, 2024. At this time, we believe amounts owed by TriRx are collectible and we will continue to assess collectibility. Further, we have rights to certain collateral in the event of a default and we continue to monitor the value of this collateral.

BexCaFe Arrangement

In June 2022, we signed a license agreement with BexCaFe, LLC (BexCaFe) for the development and commercialization of products related to Bexacat, an oral treatment intended to reduce glucose levels in diabetic cats. BexCaFe held the rights to the compound through a license agreement with similar terms and conditions. We will incur all development and regulatory costs associated with the products. Based on the guidance in Accounting Standards Codification (ASC) 810, Consolidation, we determined that BexCaFe represents a variable interest entity and that we are the primary beneficiary of BexCaFe because the terms of the license give us the power to direct the activities that most significantly impact the entity’s economic performance. As a result, we consolidated BexCaFe, a development-stage company with no employees that did not meet the definition of a business, as of the date we signed the license agreement. Upon initial consolidation of BexCaFe, we measured an IPR&D asset at its fair value of $59 million and recorded liabilities totaling $59 million, which included contingent consideration of $49 million based on the fair value of estimated future milestone payments and sales royalties owed under the license agreement. ~~The initial fair value of the contingent payments was calculated based on an income approach, with payments adjusted for probability of success and then discounted to a present value.~~ There is no minimum payout due on the contingent consideration and the maximum payout related to sales royalties is unlimited. Since BexCaFe did not meet the definition of a business, no goodwill was recorded and immediately after initial consolidation, we expensed the IPR&D asset because we concluded that it did not have an alternative future use.


			~~2023 Q1 Form 10-Q \|~~ 13

~~Table of Contents~~

During the ~~three~~six months ended ~~March 31,~~June 30, 2023, we paid $13 million to BexCaFe in connection with development/regulatory milestones achieved upon U.S. ~~FDA~~Food and Drug Administration (FDA) approval of the original new animal drug application for Bexacat in December 2022. Remaining contingent consideration liabilities of $36 million ~~are~~were included in other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheet as of ~~March 31,~~June 30, 2023.

Subsequent to the effective date of the license agreement, our consolidated financial statements include the assets, liabilities, operating results and cash flows of BexCaFe. Based on the guidance in ASC 810, income and expense between us and BexCaFe have been eliminated against the income or expense included in the financial statements of BexCaFe. The resulting amounts after the effect of these eliminations were included in our condensed consolidated financial statements for the three months ended March 31, 2023 and were not material.

Note 6.5. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. ~~As discussed further below, restructuring~~Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with ~~our~~ recent acquisitions, including the acquisition of Bayer Animal Health, we have also incurred costs associated with executing transactions and integrating acquired ~~operations, which may include expenditures for banking, legal, accounting and other similar services.~~operations. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash ~~expenses associated with our tangible and intangible assets~~impairment charges can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible assets and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. ~~See Note 2: Basis~~


			2023 Q2 Form 10-Q \| 12

Ta le of ~~Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.~~Contents

Components of asset impairment, restructuring and other special charges ~~are~~were as follows:

Three Months Ended March 31,
2023 2022
Restructuring charges (credits):
Severance and other costs (1)
$ — $ (7)
Facility exit costs — 1
Acquisition related charges:
Transaction and integration costs (2)
40 24
Non-cash and other items:
Asset write-down (3)
— 22
Total expense $ 40 $ 40


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022

Restructuring charges (credits)(1)	$	—	$	(1)	$	—	$	(7)

Acquisition related charges(2)	35		26		75		50

Non-cash and other items:
Asset impairment (3)	—		59		—		81


Settlements and other	—		2		—		2

Total expense	$	35	$	86	$	75	$	126

(1)~~2022~~Restructuring credits ~~primarily~~in 2022 relate to adjustments resulting from the reversal of severance accruals associated with 2021 restructuring programs, resulting from final negotiations and certain restructured employees filling open positions.

(2)~~Transaction costs represent external~~Acquisition related charges include transaction costs directly related to acquiring businesses, ~~and primarily include~~such as expenditures for banking, legal, accounting, consulting and other similar ~~services. Integration costs represent internal~~services, and ~~external incremental costs directly related to integrating acquired businesses, including the acquisition~~integration charges inclusive of ~~Bayer Animal Health (e.g., expenditures for consulting,~~ system and process integration and product ~~transfers), as well as~~transfers and independent company stand-up costs related to the implementation of new systems, programs and processes.

(3)Asset impairments include a charge of $59 million in the second quarter of 2022 ~~includes~~related to the ~~finalization~~write-off of ~~the write-down charge upon the final sale of the Speke site. See~~an IPR&D asset with no alternative future use licensed from BexCaFe (see Note 5:4. Acquisitions, Divestitures and Other Arrangements for further ~~discussion.~~


			~~2023 Q1 Form 10-Q \|~~ 14

~~Table~~discussion) and a $22 million charge related to the finalization of ~~Contents~~the write-down upon sale of the Speke site during the first quarter of 2022.

The ~~following table summarizes the activity~~changes in our ~~reserves established in connection with~~ restructuring ~~activities:~~reserve during the six months ended June 30, 2023, were as follows:

~~Severance~~

~~Balance at December 31, 2021~~

~~126~~

~~Reserve adjustments~~

~~(7)~~

~~Cash paid~~

~~(42)~~

~~Foreign currency translation adjustments~~

~~(1)~~

~~Balance at March 31, 2022~~

Balance at December 31, 2022

Cash paid

~~(24)~~(28)

~~Foreign currency translation adjustments~~

—

Balance at ~~March 31,~~June 30, 2023

128

These reserves ~~relate to certain restructuring programs initiated in 2021 and are~~were included inwithin other current liabilities and other noncurrent liabilities on our condensed consolidated balance sheets based on the timing of when the obligations are expected to be paid, which can vary due to certain ~~country~~country-specific negotiations and regulations. ~~As of March 31, 2023, we expect to pay approximately $7 million over the next 12 months. We believe that the reserves are adequate.~~

Note 7.6. Inventories

~~We state all inventories~~Inventories are stated at the lower of cost orand net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
March 31, 2023 December 31, 2022
Finished products $ 749 $ 725
Work in process 605 605
Raw materials and supplies 299 266
Total 1,653 1,596
Decrease to LIFO cost (57) (58)
Inventories $ 1,596 $ 1,538


	June 30, 2023		December 31, 2022
Finished products	$	834	$	783
Work in process	773		683
Raw materials and supplies	141		130
Total	1,748		1,596
Decrease to LIFO cost	(58)		(58)
Inventories	$	1,690	$	1,538

Note 8.7. Equity

Tangible Equity Unit (TEU) Offering

In January 2020, we issued 11 million in TEUs at the stated amount of $50 per unit. Total proceeds, net of issuance costs, were $528 million. The gross proceeds and deferred finance costs from the issuance of the TEUs were allocated 86% to equity (prepaid stock purchase contracts) and 14% to debt (TEU amortizing notes) based on the relative fair value of the respective components of each TEU. ~~See Note 9: Debt for additional information on the TEU amortizing notes.~~

The TEU prepaid stock purchase contracts were converted into shares of our common stock on February 1, 2023. Holders of our TEUs received 1.5625 shares of our common stock based on the maximum settlement rate for the applicable market value being below $32.00. In total, we issued approximately 17 million shares to holders in connection with the settlement.


			2023 Q1Q2 Form 10-Q \| 1513

~~Table~~Ta le of Contents

Note 9.8. Debt

Long-term debt consisted of the following:


		March 31, 2023		December 31, 2022			June 30, 2023		December 31, 2022
Incremental Term Facility due 2025	Incremental Term Facility due 2025	$	175	$	175	Incremental Term Facility due 2025	$	175	$	175
Incremental Term Facility due 2028	Incremental Term Facility due 2028	492		494		Incremental Term Facility due 2028	491		494
Incremental Term Facility due 2029	Incremental Term Facility due 2029	249		249		Incremental Term Facility due 2029	248		249
Term Loan B due 2027	Term Loan B due 2027	3,870		3,881		Term Loan B due 2027	3,860		3,881
Revolving Credit Facility (1)	Revolving Credit Facility (1)	200		—		Revolving Credit Facility (1)	250		—
4.272% Senior Notes due 2023(2)	4.272% Senior Notes due 2023(2)	344		344		4.272% Senior Notes due 2023(2)	344		344
4.900% Senior Notes due 2028(3)	4.900% Senior Notes due 2028(3)	750		750		4.900% Senior Notes due 2028(3)	750		750
TEU Amortizing Notes due 2023 ~~(2)~~(4)	TEU Amortizing Notes due 2023 ~~(2)~~(4)	—		7		TEU Amortizing Notes due 2023 ~~(2)~~(4)	—		7

Unamortized debt issuance costs	Unamortized debt issuance costs	(60)		(64)		Unamortized debt issuance costs	(56)		(64)
		6,020		5,836			6,062		5,836
Less current portion of long-term debt	Less current portion of long-term debt	381		388		Less current portion of long-term debt	39		388
Total long-term debt	Total long-term debt	$	5,639	$	5,448	Total long-term debt	$	6,023	$	5,448

(1)During the ~~three~~six months ended ~~March 31,~~June 30, 2023, we drew $250 million on our ~~revolving credit facility~~Revolving Credit Facility to fund working capital needs. Our Revolving Credit Facility provides up to $750 million in borrowing capacity (with incremental capacity if certain conditions are met), bears interest at Term SOFR plus 2.10% and matures in August 2027.

(2)The 4.272% Senior Notes due 2023, issued in August 2018, have been subject to interest rate increases since issuance related to credit rating agency downgrades. As of June 30, 2023, these notes bear interest at a rate of 6.022%. As discussed further below, on August 7, 2023, we redeemed the 4.272% Senior Notes due 2023 in full.

(3)The 4.900% Senior Notes due 2028, issued in August 2018, have been subject to interest rate increases since issuance related to credit rating agency downgrades. As of June 30, 2023, these notes bear interest at a rate of 6.650%.

(4)The TEU ~~amortizing notes~~Amortizing Notes due 2023 matured on February 1, 2023 (see Note 7. Equity for further information).

2023 Financing

On August 3, 2023, we entered into a new $300 million secured term facility (the "Securitization Facility") that is secured and collateralized by our U.S. Net Eligible Receivables Balance (as defined within the applicable agreement). Of the maximum borrowing capacity under the Securitization Facility of $300 million, $250 million was drawn on August 3, 2023. The Securitization Facility will require monthly interest payments over its three-year term at a variable rate based on Term SOFR plus 125 basis points, and our borrowing capacity under the Securitization Facility will be subject to fluctuation over time based on the level of our borrowing base, which is correlated to our U.S. Net Eligible Receivables Balances. The full, outstanding balance of the Securitization Facility will be due on July 31, 2026. On August 7, 2023, we utilized the proceeds from the Securitization Facility, in addition to a $100 million draw on our Revolving Credit Facility on August 4, 2023, to redeem in full the 4.272% Senior Notes due 2023. As the 4.272% Senior Notes due 2023 have been refinanced with long-term financing, they are reflected within long-term debt on our condensed consolidated balance sheet as of June 30, 2023. The early redemption of the 4.272% Senior Notes due 2023 has satisfied all obligations and commitments thereunder.

Subsequent to the issuance of the Securitization Facility and the redemption of the 4.272% Senior Notes due 2023, as of the date of this filing, approximately 75% of our long-term indebtedness now bears interest at a fixed-rate (including variable-rate converted to fixed-rate through the use of interest rate swaps - see Note 9. Financial Instruments for further information).

We were in compliance with all of our debt covenants as of ~~March 31, 2023.~~June 30, 2023, and remain in compliance subsequent to entering into the new Securitization Facility.

Note ~~10.~~9. Financial Instruments ~~and Fair Value~~

~~Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of~~To manage our customers on a regular basis, monitor economic conditions and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.

~~A large portion of our cash is held by a few major financial institutions. We monitor the~~ exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value.

We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $27 million as of March 31, 2023 and ~~December 31, 2022. Unrealized net gains and losses on our investments for the three months ended March 31, 2023 and 2022 were immaterial.~~


			~~2023 Q1 Form 10-Q \|~~ 16

~~Table of Contents~~

The following table summarizes the fair value information at March 31, 2023 and December 31, 2022 for foreign exchange contract assets (liabilities), investments, contingent consideration liabilities and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:

Fair Value Measurements Using
Financial statement line item Carrying
Amount Quoted Prices in Active Markets for Identical Assets
(Level 1) Significant
Other Observable Inputs
(Level 2) Significant
Unobservable
Inputs
(Level 3) Fair
Value
March 31, 2023
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments $ 28 $ — $ 28 $ — $ 28
Prepaid expense and other - forward-starting interest rate contracts designated as cash flow hedges 8 — 8 — 8
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges 3 — 3 3
Other noncurrent assets - investments 6 6 — — 6
Other current liabilities - foreign exchange contracts not designated as hedging instruments (25) — (25) — (25)
Other current liabilities - contingent consideration (23) — — (23) (23)
Other noncurrent liabilities - contingent consideration (12) — — (12) (12)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges (9) — (9) — (9)
Long-term debt, including current portion (6,080) — (5,891) — (5,891)
December 31, 2022
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments $ 76 $ — $ 76 $ — $ 76
Prepaid expenses and other - forward-starting interest rate contracts designated as cash flow hedges 14 — 14 — 14
Other noncurrent assets - forward-starting interest rate contracts designated as cash flow hedges 10 — 10 — 10
Other noncurrent assets - investments 7 7 — — 7
Other current liabilities - foreign exchange contracts not designated as hedging instruments (64) — (64) — (64)
Long-term debt, including current portion (5,900) — (5,711) — (5,711)

~~We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.~~


			~~2023 Q1 Form 10-Q \|~~ 17

~~Table of Contents~~

Contingent consideration liabilities totaling $35 million as of March 31, 2023 related to contingent consideration associated with our acquisition of certain assets of NutriQuest during the first quarter of 2023. We may pay up to $85 million in cash consideration which is contingent upon the achievement of specified sales, approval and geographic expansion milestones as outlined in the asset purchase agreement. The fair values of the contingent consideration liabilities were estimated using the Monte Carlo simulation model and a probability weighted expected return method. Both methods use significant inputs that are not observable in the market, representing Level 3 inputs, including those relating to revenue forecasts, discount rates, and volatility. See Note 5: Acquisitions, Divestitures and Other Arrangements for further discussion.

~~Derivative Instruments and Hedging Activities~~

~~We are exposed~~ to market risks, such as changes in foreign currency exchange rates and interest ~~rates. To manage the volatility related to these exposures,~~rates, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. ~~Additionally, we~~We also assess ~~both at inception and~~ at least quarterly thereafter whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating activities section of the condensed consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing activities section of the condensed consolidated statements of cash flows. Further, we do not offset derivative assets and liabilities on the condensed consolidated balance sheets. Our outstanding positions are discussed below.


			2023 Q2 Form 10-Q \| 14

Ta le of Contents

Derivatives not designated as hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. ~~These derivative financial instruments primarily offset exposures in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.~~ Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other expense (income), net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. As of ~~March 31,~~June 30, 2023 and December 31, 2022, we had outstanding foreign exchange contracts with aggregate notional amounts of ~~$912~~$988 million and $784 million, respectively.

The amount of net (losses) gains ~~(losses)~~ on derivative instruments not designated as hedging instruments, recorded in other expense (income), net were as follows:

Three Months Ended March 31,
2023 2022
Foreign exchange forward contracts (1)
$ 2 $ (8)


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Foreign exchange forward contracts (1)	$	(1)	$	(7)	$	1	$	(15)

(1)These amounts were substantially offset in other expense (income), net by the effect of changing exchange rates on the underlying foreign currency exposures.


			~~2023 Q1 Form 10-Q \|~~ 18

~~Table of Contents~~

Derivatives designated as hedges

~~We are subject~~To manage our exposure to variable interest rate risk, ~~with regard to our existing floating-rate debt, and~~ we utilize interest rate swap contracts to ~~mitigate the variability in cash flows by~~ effectively ~~converting the floating-rate~~convert our variable-rate debt into fixed-rate debt. We recognize any differences between the variable interest rate payments and the fixed interest rate settlements with the swap counterparties as an adjustment to interest expense, net of capitalized interest over the life of the swaps. We have designated our interest rate swaps as cash flow hedges and record them at fair value on the condensed consolidated balance sheets. Changes in the fair value of the hedges are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2.2 in the fair value hierarchy (see Note 10. Fair Value for further information). Our outstanding forward-starting interest rate swaps ~~have~~had maturities ranging between 2023 and ~~2025~~2028, with aggregate notional amounts of $3,800 million and $3,050 million as of ~~March 31,~~June 30, 2023 and December 31, ~~2022.~~ 2022, respectively.

In March 2023, we entered into new interest rate swap agreements with a combined notional amount of $1,000 million, which will become effective on October 1, 2023, following the maturity of certain current swaps with the same combined notional amount. ~~The transaction effectively extends~~Additionally, on May 1, 2023, we entered into new interest rate swap agreements with a combined notional amount of $750 million, which became effective on June 1, 2023, and mature in August 2028. As of June 30, 2023, when factoring in the ~~maturity from 2023~~$3,800 million of variable rate debt converted to ~~2025 and will result in a change~~fixed-rate through the use of ~~the weighted average fixed~~interest rate ~~from 4.4% to 4.1%~~swaps, our weighted-average effective interest rate on ~~the effective date.~~

our outstanding indebtedness was 6.28%.

The amounts of net gains (losses) on cash flow hedges recorded, net of tax in other comprehensive income ~~are~~(loss) were as follows:

Three Months Ended March 31,
2023 2022
Forward-starting interest rate swaps $ (48) $ 109


	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Forward-starting interest rate swaps	$	29	$	8	$	(19)	$	117

During the three months ended ~~March 31,~~June 30, 2023 and 2022, activity on cash flow hedges recorded in other comprehensive income (loss) included ~~losses~~gains of ~~$21~~$55 million and ~~gains~~$33 million, net of ~~$109 million,~~tax, respectively, related to mark-to-market adjustments. ~~There was no tax effect for~~During the ~~three~~six months ended ~~March 31,~~June 30, 2023 and 2022, ~~after the application~~activity on cash flow hedges recorded in other comprehensive income (loss) included gains of ~~the U.S. valuation allowance. See Note 11: Income Taxes for further discussion.~~

$33 million and $142 million, net of tax, respectively, related to mark-to-market adjustments.

In April 2022 and September 2022, we ~~took advantage of market opportunities to restructure our~~settled certain existing interest rate ~~swap portfolio. We unwound the existing~~ swaps and simultaneously entered into new agreements with the same notional ~~amounts~~amount and covering the same ~~tenors.~~tenor. As a result, we received cash settlements of $132 million and $75 million, respectively, the former of which was reflected in net cash from operating activities in the ~~respective periods. These gains were initially recognized in accumulated other comprehensive loss and are reclassified to interest expense, net~~condensed consolidated statement of ~~capitalized interest over~~cash flows for the ~~period during which the related interest payments are made. During the three~~six months ended ~~March 31, 2023, we reclassified $27 million of gains relating to our terminated interest rate swaps from accumulated other comprehensive loss to interest expense, net of capitalized interest.~~

June 30, 2022.

During the three months ended ~~March 31,~~June 30, 2023 and 2022, we reclassified $4$29 million and $3$1 million of net gains, respectively, into interest expense, net of capitalized interest. During the six months ended June 30, 2023 and 2022, we reclassified $59 million of net gains and $2 million of net losses, respectively, into interest ~~expense.~~expense, net of capitalized interest. Over the next 12 months, we expect to reclassify a gain of ~~$87~~$108 million ~~which includes $75 million relating to the interest rate swap settlements,~~ to interest expense, net of capitalized interest.


			2023 Q2 Form 10-Q \| 15

Ta le of Contents

Note 10. Fair Value

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on a framework that utilizes the inputs market participants use to determine the fair value of an asset or liability and establishes a fair value hierarchy to prioritize those inputs. Level 1 fair value measurements are based on quoted prices in active markets for identical assets or liabilities. We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. Our Level 3 fair value measurements, which include the value of contingent consideration as of June 30, 2023, are based on unobservable inputs based on little or no market activity.

The following table summarizes the fair value information at June 30, 2023 and December 31, 2022 for assets and liabilities measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt, for which fair value is disclosed on a recurring basis:


			Fair Value Measurements Using
Financial statement line item	Carrying Amount		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value
June 30, 2023
Recurring fair value measurements
Prepaid expenses and other - derivative instruments	$	40	$	—	$	40	$	—	$	40
Other noncurrent assets - derivative instruments	51		—		51		—		51
Other noncurrent assets - investments with readily determinable fair value	9		9		—		—		9
Other current liabilities - derivative instruments	(35)		—		(35)		—		(35)
Other current liabilities - contingent consideration	(13)		—		—		(13)		(13)

Other noncurrent liabilities - contingent consideration	(25)		—		—		(25)		(25)
Financial instruments not carried at fair value
Long-term debt, including current portion	(6,118)		—		(5,942)		—		(5,942)






December 31, 2022

Recurring fair value measurements
Prepaid expenses and other - derivative instruments	$	90	$	—	$	90	$	—	$	90
Other noncurrent assets - derivative instruments	10		—		10		—		10
Other noncurrent assets - investments with readily determinable fair value	7		7		—		—		7

Other current liabilities - derivative instruments	(64)		—		(64)		—		(64)

Financial instruments not carried at fair value
Long-term debt, including current portion	(5,900)		—		(5,711)		—		(5,711)

We also had investments without readily determinable fair values and equity method investments, which were classified as other noncurrent assets on our condensed consolidated balance sheets totaling $27 million as of June 30, 2023 and December 31, 2022. These investments are not recorded at fair value on a recurring basis, and as such, are not included in the fair value table above.

Contingent consideration liabilities totaling $38 million as of June 30, 2023 related to our acquisition of certain assets of NutriQuest during the first quarter of 2023 (see Note 4. Acquisitions, Divestitures and Other Arrangements for further information). We may pay up to $85 million in cash consideration, which is contingent upon the achievement of specific development, sales and geographic expansion milestones as outlined in the asset purchase agreement. The fair values of the contingent consideration liabilities were estimated using the Monte Carlo


			2023 Q2 Form 10-Q \| 16

Ta le of Contents

simulation model, consisting of Level 3 inputs not observable in the market, including estimates relating to revenue forecasts, discount rates and volatility.

Note 11. Income Taxes


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Income tax expense (benefit)	$	18		$	(4)		$	23		$	20
Effective tax rate	(23.0)		%	28.6		%	79.9		%	32.3		%

Three Months Ended March 31,
2023 2022
Income tax expense $ 5 $ 24
Effective tax rate 4.4 % 31.6 %
For the three and six months ended June 30, 2023, we recognized income tax expense of $18 million and $23 million, respectively. Our effective tax rates of (23.0)% and 79.9%, respectively, differ from the statutory income tax rates due to the earnings mix of income in jurisdictions with statutory tax rates higher than the U.S. and losses in the U.S. and various foreign affiliates for which there was no tax benefit, as valuation allowances have been established in those jurisdictions.

For the three and six months ended June 30, 2022, we recognized an income tax benefit of $4 million and income tax expense of $20 million, respectively. Our effective tax rates of 28.6% and 32.3%, respectively, differ from the statutory income tax rate largely due to changes in the earnings mix between periods resulting in projected losses in the U.S. The U.S. federal and state losses were subject to valuation allowances. The income tax (benefit) expense was partially offset by a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps during the three months ended June 30, 2022.

We were included in ~~Lilly's~~Eli Lilly and Company's (Lilly) U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with our initial public offering (IPO), the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 to 2018 began in ~~the fourth quarter of~~ 2019 and remains ongoing. It is possible that the examination of these tax years could conclude within the next 12 months. Final resolution of certain matters is dependent upon several factors, including the potential for formal administrative proceedings.


			~~2023 Q1 Form 10-Q \|~~ 19

~~Table of Contents~~

For the three months ended March 31, 2023, we recognized income tax expense of $5 million. Our effective tax rate of 4.4% differs from the statutory income tax rate due to jurisdictional earnings mix of projected income in lower tax jurisdictions, partially offset by losses in the U.S. and a Southeast Asia affiliate for which there is no tax benefit as valuation allowances have been established in those countries.

For the three months ended March 31, 2022, we recognized income tax expense of $24 million. Our effective tax rate of 31.6% differs from the statutory income tax rate largely due to certain research and experimentation costs being capitalized beginning January 1, 2022, as provided under the Tax Cuts and Jobs Act. This increased the expected profits in jurisdictions with higher statutory tax rates as well as expected U.S. international tax inclusions, which are partially offset by utilization of net operating losses and valuation allowance release in the U.S.

Note 12. Commitments and Contingencies

Legal Matters

We are party to various legal actions that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded when it is deemed probable that we will incur a loss and we can formulate a reasonable estimate of that loss.

Seresto Class Action Lawsuits and EPA Safety Review

Claims seeking actual damages, injunctive relief and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the Seresto collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. In June 2023, the parties agreed on the monetary terms of a potential settlement of the consolidated class action lawsuits. As a result, we determined that an accrual of $15 million was appropriate, given a settlement is now considered both estimable and probable as of June 30, 2023. The parties must still reach agreement on non-monetary terms, and any settlement, if reached, is subject to approval by the court, and likely will be subject to other conditions. We have recorded this $15 million accrual provision within other current liabilities on our condensed consolidated balance sheet, with a corresponding charge included within other expense (income), net on our condensed consolidated statements of operations for the three and six months ended June 30, 2023.

Also, in January 2023, a lawsuit seeking damages for alleged negligence, breach of statutory regulations, breach of statutory duties and deceptive marketing was filed in Israel against Elanco and other parties, arising out of the use of Seresto and Foresto™ flea and tick collars for cats and dogs that are marketed and sold in Europe and in Israel. We intend to defend our position vigorously, and as of the date of this filing, we are unable to estimate the probability of loss or range of loss, if any.

Further, in March 2021, a member of the U.S. House of Representatives who was serving as a subcommittee chair requested that Elanco produce certain documents and information related to the Seresto collar and further made a request to temporarily recall Seresto collars from the market. On June 15, 2022, the subcommittee held a hearing at which our CEO testified. During and after the hearing, the subcommittee chair repeated his request that Elanco voluntarily recall the collars and also requested that the U.S. Environmental Protection Agency (EPA) commence administrative proceedings that would allow the EPA to remove Seresto from the market.


			2023 Q2 Form 10-Q \| 17

Ta le of Contents

Seresto is a pesticide registered with the EPA. In April 2021, a non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. In response to the EPA's request for comments from the public on the petition, we submitted a comment to the EPA supporting the safety profile of Seresto and engaged in discussions with the EPA. On July 13, 2023, the EPA announced their completion of a comprehensive, multi-year review, with support from the FDA, of the Seresto flea and tick collar and confirmed the continued registration of the collar, denying the citizen's petition. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA registered pet products. Based on comprehensive data from the review, the EPA concluded that Seresto continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose unreasonable risk of harm.

Additional Legal Matters

For the litigation matters discussed below ~~for which a~~we either believe loss is ~~reasonably possible, we~~not probable or are unable to estimate the possible loss or range of loss, if any. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolutions cannot be predicted. As of ~~March 31,~~June 30, 2023 and December 31, 2022, we had no material liabilities established related to the litigation ~~as there were no significant claims which were probable and estimable.~~

matters mentioned below.

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco and certain executives. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint adding additional claims against Elanco, certain executives and other individuals. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. WeOn January 13, 2021, we filed a motion to dismiss, and on ~~January 13, 2021. On~~ August 17, 2022, the Court issued an order granting our motion to dismiss the case without prejudice. On October 14, 2022, the plaintiffs filed a motion for leave to amend the complaint. WeOn December 7, 2022, we filed an opposition to the plaintiffs' motion, ~~on December 7, 2022.~~and we were awaiting the Court’s decision as of June 30, 2023. We believe the claims made in the case are meritless, and we intend to vigorously defend our position.

On October 16, 2020, a shareholder class action lawsuit captioned Saffron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives and other individuals and entities. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or ~~5.00%~~ TEUs issued in connection with the public offering. From February 2021 to August 2022, this case was stayed in deference to Hunter v. Elanco Animal Health Inc. On October 24, 2022, we filed a motion to dismiss. ~~The~~On December 23, 2022, the plaintiffs filed their opposition to the motion to dismiss. Prior to the ruling on the motion to dismiss, on ~~December 23, 2022.~~June 8, 2023, the plaintiffs filed a motion for leave to file a second amended complaint, which is now the operative complaint. Our motion to dismiss the complaint is due on August 7, 2023. We believe the claims made in the case are meritless, and we intend to vigorously defend our position.


			~~2023 Q1 Form 10-Q \|~~ 20

~~Table of Contents~~

Claims seeking actual damages, injunctive relief and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of ~~Seresto™, a non-prescription flea and tick collar for cats and dogs. During 2021, putative class action lawsuits were filed in federal courts in the U.S. alleging that the~~ ~~Seresto~~ collars contain pesticides that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. In August 2021, the lawsuits were consolidated by the Judicial Panel on Multidistrict Litigation, and the cases were transferred to the Northern District of Illinois. We are vigorously defending these lawsuits. In January 2023, a lawsuit seeking damages for alleged negligence, breach of statutory regulations, breach of statutory duties and deceptive marketing was filed in Israel against Elanco among other parties, arising out of the use of ~~Seresto~~ ~~and~~ ~~Foresto™, a flea and tick collar for cats and dogs that is marketed and sold in Europe and in Israel. We intend to defend our position vigorously.~~

~~Further, in March 2021, a member of the U.S. House of Representatives who was serving as a subcommittee chair requested that Elanco produce certain documents and information related to the~~ ~~Seresto~~ ~~collar and further made a request to temporarily recall~~ ~~Seresto~~ collars from the market. On June 15, 2022, the subcommittee held a hearing at which our CEO testified. During and after the hearing, the subcommittee chair repeated his request that Elanco voluntarily recall the collars and also requested that the Environmental Protection Agency (EPA) commence administrative proceedings that would allow the EPA to remove ~~Seresto~~ ~~from the market.~~

~~Seresto~~ ~~is a pesticide registered with the EPA. In April 2021, a non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel~~ ~~Seresto’s~~ pesticide registration and suspend the registration pending cancellation. In response to the EPA's request for comments from the public on the petition, we submitted a comment to the EPA supporting the safety profile of ~~Seresto~~ and have since engaged in discussions with the EPA. Data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. We believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for ~~Seresto, and it remains available to consumers globally.~~

In the third quarter of 2019, Tevra Brands, LLC (Tevra) filed a complaint in the U.S. District Court of the Northern District of California, alleging that Bayer Animal Health (acquired by us in August 2020) had been involved in unlawful, exclusive dealing and tying of its flea and tick products Advantage, Advantix and Seresto and maintained a monopoly in the market. The complaint was amended in March 2020 and then dismissed in September 2020 with leave to amend. A second amended complaint was filed in March 2021 and realleges claims of unlawful exclusive dealing related to Advantage and Advantix and monopoly maintenance. A motion to dismiss the second amended complaint was denied in January 2022. Tevra’s demands include both actual and treble damages. The trial is scheduled infor July 2024. We intend to defend our position vigorously.

Regulatory Matters

On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so.


			2023 Q2 Form 10-Q \| 18

Ta le of Contents

Management believes that its actions were appropriate. At this stage, we are unable to estimate the range of any potential loss associated with this matter.

Other Commitments

As of ~~March 31,~~June 30, 2023, we ~~have~~had a lease commitment that has not yet commenced for our new corporate headquarters in Indianapolis, Indiana. Total minimum lease payments are estimated to be approximately $378 million over a term of 25 years, excluding extensions. Final lease payments may vary depending on the actual cost of certain construction activities. Lease commencement is expected in 2025.


			~~2023 Q1 Form 10-Q \|~~ 21

~~Table of Contents~~

The land for our new corporate headquarters is located in a Tax Increment Finance District, and the project is, in part, funded through Tax Incremental Financing (TIF) through an incentive agreement between us and the City of Indianapolis. The agreement provides for an estimated total incentive of $64 million to be funded by the City of Indianapolis in connection with the future tax increment revenue generated from the developed property. In December 2021, as part of a funding and development agreement entered into between us and the developer, we made a commitment to use the expected TIF proceeds towards the cost of developing and constructing the headquarters. In exchange, the developer reimbursed us up to the $64 million commitment in 2021. During 2022, we refunded approximately $15 million of the TIF proceeds to the developer. As a result, it is our expectation that our future lease payments will be reduced. The remaining accrued incentive iswas included in other noncurrent liabilities on our condensed consolidated balance sheets and will be amortized over the lease term beginning on the commencement date and offset future rent expense.

~~Note 13. Geographic Information~~

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both pets and farm animals. Consistent with our operational structure, our CEO, as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.

~~Our products include~~ ~~AviPro™, Baytril™, Catosal™, Clynav™, Cydectin™, Denagard™, Maxiban™, Rumensin™~~, ~~Pulmotil™~~ ~~and other products for livestock, poultry and aquaculture, as well as~~ ~~Advantage™, Advantix™, Advocate™~~ ~~(with several brands collectively referred to as the~~ ~~Advantage Family), Credelio™, TruCan™~~, ~~Galliprant™, Interceptor™ Plus,Seresto, Trifexis™~~ ~~and other products for pets.~~

We have a single customer that accounted for 9% and 10% of revenue for the three months ended March 31, 2023 and 2022, respectively. Product sales with this customer resulted in accounts receivable of $66 million and $73 million as of March 31, 2023 and December 31, 2022, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

~~Selected geographic area information was as follows:~~

Three Months Ended March 31,
2023 2022
Revenue
United States $ 543 $ 522
International 714 704
Revenue $ 1,257 $ 1,226


			~~2023 Q1 Form 10-Q \|~~ 22

~~Table of Contents~~

Note ~~14.~~13. Earnings Per Share

We compute basic earnings (loss) per share by dividing net income (loss) available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements. We also had variable common stock equivalents related to the TEU prepaid stock purchase contracts during the three and six months ended ~~March 31,~~June 30, 2022, and in the first quarter of 2023 through the settlement date of February 1, 2023 (see Note 8:7. Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards converted their holdings into common stock and that could have occurred if holders of unsettled TEUs had converted their holdings into common stock prior to the February 1, 2023 settlement date. The weighted average number of potentially dilutive shares outstanding iswas calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares ~~are~~were not included in the calculation of diluted earnings (loss) per share.

Basic and diluted ~~earnings per share are calculated~~weighted-average shares outstanding were as follows:

Three Months Ended March 31,
2023 2022
Net income available to common shareholders $ 103 $ 51
Determination of shares:
Basic weighted average common shares outstanding (1)
491.1 488.0
Assumed conversion of dilutive common stock equivalents (2)
1.7 4.2
Diluted weighted average shares outstanding 492.8 492.2
Earnings per share (3)
Basic $ 0.21 $ 0.10
Diluted $ 0.21 $ 0.10


	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022

Determination of shares:
Basic weighted-average common shares outstanding (1)	492.6	488.4	491.8	488.2
Assumed conversion of dilutive common stock equivalents (2)	—	—	0.9	3.9
Diluted weighted-average shares outstanding	492.6	488.4	492.7	492.1

(1)The TEU prepaid stock purchase contracts were convertible into a minimum of 14.3 million shares or a maximum of 17.2 million shares. The minimum 14.3 million shares were included in the calculation of basic weighted average shares from January 22, 2020 to February 1, 2023. The 17.2 million shares that were ultimately issued were included in the calculation of basic weighted average shares ~~after~~subsequent to the settlement date ~~from~~of February 1, ~~2023 to March 31,~~ 2023.

(2)For the three months ended ~~March 31,~~June 30, 2023 and 2022, approximately ~~1.4~~2.0 million and ~~0.1~~3.2 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the six months ended June 30, 2023 and 2022, approximately 1.8 million and 1.6 million, respectively, of potential common shares were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.

~~(3)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.~~


			2023 Q1Q2 Form 10-Q \| 2319

~~Table~~Ta le of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Form 10-Q. Certain statements in this Item 2 of Part I of this Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" of this Form 10-Q, in Item 1A, "Risk Factors" of Part II of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our 2022 Form 10-K, may cause our actual results, financial position and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.

Business Overview

Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives. We advance our vision by offering products in ~~two primary categories: pet health~~the Pet Health and ~~farm animal.~~

Farm Animal product categories.

We offer a diverse portfolio of approximately 200 brands that make us a trusted partner to pet owners, veterinarians and farm animal producers. Our products are generally sold worldwide to third-party distributors and independent retailers and directly to farm animal producers and veterinarians. With the acquisition of Bayer Animal Health in 2020, we expanded our presence in retail and e-commerce channels, allowing our customers to shop where and how they want.

Key Trends and Factors Affecting Our Results of Operations

~~We operate our~~Acquisition and Integration Activity: As previously disclosed, in April 2023, we successfully completed the integration of the Bayer Animal Health business into Elanco's Enterprise Resource Planning (ERP) system. In connection with the integration, we communicated commercial shipping blackout periods that occurred in April, and, given this timing, we believe certain customers modified purchasing habits, which we estimate caused a shift of revenue from the second quarter of 2023 to the first quarter of approximately $90 million to $110 million. In addition, we extended payment terms related to approximately $35 million of revenue in the first quarter of 2023 in certain international markets, driven by the duration of the aforementioned blackout periods. While first quarter 2023 revenues benefited from this shift in purchases, this resulted in a ~~single segment directed at fulfilling~~corresponding decrease in revenues during the second quarter of 2023.

During the six months ended June 30, 2023, we continued to incur costs related to integration activities, including the build out of processes and systems to support our ~~vision~~global organization. Integration costs totaled $75 million for the six months ended June 30, 2023. We anticipate some additional costs through 2023 as we finalize these integration activities.

Macroeconomic Factors: Our operations are exposed to and are impacted by various global macroeconomic factors. We face continuing market and operating challenges across the globe due to, among other factors, the Russia-Ukraine conflict, supply chain disruption, higher interest rates and inflationary pressures. Continued evolution of ~~food~~these conditions has led to economic slowdowns in certain countries and/or regions and ~~companionship enriching life – all~~has also led to ~~advance~~volatility in consumer behavior, particularly impacting our over-the-counter (OTC) retail parasiticide products. We expect these global macroeconomic pressures to continue through 2023.

While there has been an overall improvement in the conditions related to the COVID-19 pandemic in 2023 as compared to 2022, we may continue to experience geographical variations. The extent to which the COVID-19 pandemic may continue to impact our financial condition and results of operations remains uncertain.

Russia-Ukraine Conflict: As a global animal health leader, we have an obligation to support the health of animals ~~people~~ and people. At the ~~planet. We advance~~center of that work is ensuring access and availability of food and avoiding the spread of disease. At this time, we are limiting our ~~vision by offering products~~business in ~~these two primary categories:~~

~~Pet Health:~~ ~~Our pet health portfolio is focused on parasiticides, vaccines and therapeutics. We have one of~~Russia to only the ~~broadest parasiticide portfolios in the pet health sector based on indications, species and formulations, with~~essential products that ~~protect pets~~support these needs, while complying with all imposed sanctions. We do not currently manufacture products or source any materials from ~~worms, fleas and ticks. Our~~ ~~Seresto~~ ~~and~~ ~~Advantage Family~~ ~~products are over-the-counter treatments for the elimination and prevention, respectively, of fleas and ticks, and complement our prescription parasiticide products,~~ ~~Credelio~~, ~~Interceptor Plus~~ ~~and~~ ~~Trifexis~~. Our vaccines portfolio provides differentiated prevention coverage for a number of important pet health risks and is available in the U.S. only. In therapeutics, we have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our ~~Galliprant~~ ~~product is one of the fastest growing osteoarthritis treatments in the U.S. Additionally, we have products that offer treatment for otitis (ear infections) with~~ ~~Claro, as well as treatments for certain cardiovascular and dermatology indications.~~

~~Farm Animal~~: Our farm animal portfolio consists of products designed to prevent, control and treat health challenges primarily focused on cattle (beef and dairy), swine, poultry and aquaculture (cold and warm water) production. Our products include medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, among others. We have a wide range of farm animal products, including ~~Rumensin~~ ~~and~~ ~~Baytril, both of which are used extensively in ruminants (e.g., cattle, sheep and goats). In poultry, our~~ ~~Maxiban~~ ~~product, is a valuable offering for the control and prevention of intestinal disease.~~


			2023 Q1Q2 Form 10-Q \| 2420

~~Table~~Ta le of Contents

~~A summary~~companies in Russia for use in our products, but to continue to support the health of animals and people, we may in the future source products in Russia because of new laws requiring products sold in Russia to be produced there as well. We do not conduct business with the Russian government. During the six months ended June 30, 2023, revenue to Russian and Ukrainian customers represented approximately 1% of our consolidated revenue. Assets held in Russia as of June 30, 2023 represented less than 1% of our consolidated assets.

Seasonality: While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. For example, based upon historical results, approximately 75% and 60% of total annual revenue contributed by our higher-margin parasiticide products Serestoand ~~net income~~Advantage Family, respectively, typically occurs during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere. Therefore, total revenue for our pet health products through the first half of 2023 is not necessarily an indication of performance during the second half of the year.

Product Development and Regulatory Update

A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we develop internally and may develop with partners and products that we are able to obtain through licenses or acquisitions, and the life cycle management of our existing products. We believe we are an industry leader in animal health R&D, with a track record of successful product innovation, business development and commercialization. For example, in July 2023 we launched our canine parvovirus monoclonal antibody in the U.S., the first and only approved therapeutic solution to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract.

Seresto: On July 13, 2023, the EPA announced their completion of a comprehensive, multi-year review, with support from the FDA, of the Seresto flea and tick collar and confirmed the continued registration of the collar. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA-registered pet products. Based on comprehensive data from the study, the EPA concluded that Seresto continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose unreasonable risk of harm. We believe the EPA's conclusions align with those of authorities worldwide, with Seresto being approved for use in more than 80 counties and supported by veterinary professionals around the globe. The robust scientific evidence continues to support Seresto's safe use.

Results of Operations

The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.

Revision of Prior Period Financial Statements Primarily Relating to Tax Valuation Allowance Adjustment

In connection with the ~~same period~~preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 ~~is as follows:~~would have caused the 2022 financial statements to be materially misstated. As a result of having to make the revisions related to this error, we made other immaterial revisions to our 2022 unaudited interim consolidated financial statements. All of the revisions have been reflected throughout this Form 10-Q.

Three Months Ended March 31,
(Dollars in millions) 2023 2022
Revenue $ 1,257 $ 1,226
Net income 103 51


			2023 Q2 Form 10-Q \| 21

Ta le of Contents


	Three Months Ended June 30,								Six Months Ended June 30,
(Dollars in millions)	2023			2022			% Change		2023			2022			% Change
Revenue	$	1,057		$	1,175		(10)	%	$	2,314		$	2,401		(4)	%
Costs, expenses and other:
Cost of sales	434			484			(10)	%	928			993			(7)	%
% of revenue	41		%	41		%	—	%	40		%	41		%	(1)	%
Research and development	81			82			(1)	%	162			163			(1)	%
% of revenue	8		%	7		%	1	%	7		%	7		%	—	%
Marketing, selling and administrative	353			343			3	%	680			666			2	%
% of revenue	33		%	29		%	4	%	29		%	28		%	1	%
Amortization of intangible assets	136			133			2	%	270			270			—	%
% of revenue	13		%	11		%	2	%	12		%	11		%	1	%
Asset impairment, restructuring and other special charges	35			86			(59)	%	75			126			(40)	%
Interest expense, net of capitalized interest	74			67			10	%	138			119			16	%
Other expense (income), net	23			(6)			NM		32			3			NM
(Loss) income before income taxes	(79)			(14)			464	%	29			61			52	%
% of revenue	(7)		%	(1)		%	(6)	%	1		%	3		%	(2)	%

Income tax expense (benefit)	18			(4)			NM		23			20			NM
Net (loss) income	$	(97)		$	(10)		870	%	$	6		$	41		85	%

Certain amounts and percentages may reflect rounding adjustments.

NM - Not meaningful

Revenue

As a global company, our products are sold in more than 90 countries, and as a result, significant portions of our revenue and expenses are recorded in currencies other than the U.S. dollar. ~~Accordingly, in any period,~~As a result, our ~~reported~~ revenue ~~expenses and resulting earnings (loss) are impacted~~is influenced by changes in foreign exchange rates. During the ~~exchange rates~~six months ended June 30, 2023 and 2022, approximately 54% and 52%, respectively, of ~~those currencies relative~~our revenue was denominated in foreign currencies. Currency movements decreased revenue by 1% and 2% for the three and six months ended June 30, 2023, respectively, compared to the ~~U.S. dollar.~~same periods in 2022.

~~Increases~~Further, increases or decreases in inventory levels in our distribution channels can positively or negatively impact our quarterly ~~and annual~~ revenue results, leading to variations in revenue. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our ~~control, including weather conditions~~control.

On a global basis, our revenue by product category for the three and ~~the COVID-19 global pandemic.~~six months ended June 30, 2023 and 2022 is summarized as follows:

~~Key Trends and Conditions Affecting Our Results of Operations~~

~~Industry Trends~~

~~The animal health industry, which includes both pets and farm animals, is a growing industry that benefits billions of people worldwide.~~

~~We believe that factors influencing growth in demand for pet medicines and vaccines include:~~

•~~increased pet ownership globally;~~

•~~pets living longer; and~~

•~~owners sharing a unique and loving bond with their pets.~~

~~As demand for animal protein grows, farm animal health is becoming increasingly important. We believe that factors influencing growth in demand for farm animal medicines and vaccines include:~~

•~~two in three people needing improved nutrition;~~

•~~increased global demand for protein, particularly poultry and aquaculture;~~

•~~natural resource constraints, such as scarcity of arable land, fresh water and increased competition for cultivated land, driving the need for more efficient food production;~~

•~~loss of productivity due to farm animal disease and death;~~

•~~increased focus on food safety and food security; and~~

•~~human population growth, increased standards of living, particularly in many emerging markets, and increased urbanization.~~

Growth in farm animal nutritional health products (enzymes, probiotics and prebiotics) is influenced, among other factors, by demand for antibiotic alternatives that can promote animal health and increase productivity.


	Three Months Ended June 30,
	Revenue				% of Total Revenue				Increase (Decrease)
(Dollars in millions)	2023		2022		2023		2022		$ Change		% Change		CC (1)
Pet Health	$	518	$	610	49	%	52	%	$	(92)	(15)	%	(14)	%
Farm Animal	527		553		50	%	47	%	(26)		(5)	%	(3)	%
Subtotal	1,045		1,163		99	%	99	%	(118)		(10)	%	(9)	%
Contract Manufacturing (2)	12		12		1	%	1	%	—		—	%	1	%
Total	$	1,057	$	1,175	100	%	100	%	(118)		(10)	%	(9)	%


			2023 Q1Q2 Form 10-Q \| 2522

~~Table~~Ta le of Contents

~~Factors Affecting Our Results of Operations~~

~~Global Macroeconomic Environment~~

Our operations are conducted globally, and we are exposed to and are impacted by various global macroeconomic factors. We face continuing market and operating challenges across the globe due to, among other factors, the Russia-Ukraine conflict, supply chain disruptions, higher interest rates and inflationary pressures. Continued evolution of these conditions has led to economic slowdowns in certain countries and/or regions. It has also led to volatility in consumer behavior, which has reduced demand due to consumption decreases and retailer destocking, particularly impacting our parasiticide products. We expect these global macroeconomic pressures to continue in 2023.

As a global animal health leader, we have an obligation to support the health of animals and people. At the center of that work is ensuring access and availability of food and avoiding the spread of disease. At this time, we are limiting our business in Russia to only the essential products that support these needs, while complying with all imposed sanctions. We do not currently manufacture products or source any materials from companies in Russia for use in our products, but to continue to support the health of animals and people, we may in the future source products in Russia because of new laws requiring products sold in Russia to be produced there as well. We do not conduct business with the Russian government. During the three months ended March 31, 2023, revenue to Russian and Ukrainian customers represented approximately 1% of our consolidated revenue. Assets held in Russia as of March 31, 2023 represented less than 1% of our consolidated assets.

While there has been an overall improvement in the conditions related to the COVID-19 pandemic in 2023 as compared to 2022, we may continue to experience geographical variations. In 2022, our operations were adversely impacted by the COVID-19 related lockdowns in China, which were lifted late in the year. The extent to which the COVID-19 pandemic may continue to impact our financial condition and results of operations remains uncertain.

~~Revision of Prior Period Financial Statements Primarily Relating to Tax Valuation Allowance Adjustment~~

In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. As a result of having to make the revisions related to this error, we made other immaterial revisions to our 2022 unaudited interim consolidated financial statements. All of the revisions are reflected throughout this Form 10-Q. See Note 2: Basis of Presentation and Summary of Significant Accounting Policies to the condensed consolidated financial statements for additional information.

~~Acquisitions of Bayer Animal Health and KindredBio~~

We have incurred expenses in connection with our acquisitions of Bayer Animal Health and KindredBio, including fees for professional services such as legal, accounting, consulting and other advisory fees and expenses. Expenses incurred in 2023 and 2022 are primarily related to integration activities. In addition, we have incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics and to expand administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources and manufacturing, to replace services previously provided by the former parent company of Bayer Animal Health. We anticipate that these additional costs will be partially offset by expected synergies. The ERP system integration of legacy Bayer Animal Health to the Elanco system is expected to be completed in the second quarter of 2023. In connection with the integration of the two systems, we specified to our customers periods of time during which product could not be shipped and increased our inventories during the fourth quarter of 2022 to ensure that our product remained available to customers. We believe certain customers modified purchasing habits due to the ERP system integration, causing a shift of revenue from the second quarter to the first quarter of 2023 of approximately $90 million to $110 million based on our high-level estimates. In addition, we extended payment terms related to approximately $35 million of revenue in the first quarter of 2023 in certain international markets, driven by the duration of the aforementioned blackout periods.


			~~2023 Q1 Form 10-Q \|~~ 26

~~Table of Contents~~

~~Product Development and New Product Launches~~

A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we develop internally and may develop through joint ventures and products that we are able to obtain through licenses or acquisitions, and the expansion of the use of our existing products. We believe we are an industry leader in animal health R&D, with a track record of product innovation, business development and commercialization.

~~Competition~~

We face intense competition globally. Competition may vary depending on the particular region, species, product category or individual product. We compete principally on the basis of product quality, price, cost-effectiveness, promotional effectiveness, new product development and product differentiation. Certain products, both existing and new products that we introduce, may compete with other branded or generic products already on the market or that are later developed by competitors. When competitors introduce new products with ease-of-use, therapeutic or cost advantages, our products may become subject to decreased sales and/or price reductions.

Our primary competitors include animal health medicines and vaccines companies such as Zoetis Inc.; Boehringer Ingelheim Vetmedica, Inc., the animal health division of Boehringer Ingelheim GmbH; and Merck Animal Health, the animal health division of Merck & Co., Inc. We also face competition globally from manufacturers of generic drugs, as well as from producers of nutritional health products, such as DSM Nutritional Products AG and Danisco Animal Nutrition, the animal health division of E.I. du Pont de Nemours and Company, a subsidiary of DowDuPont, Inc. There are also several new start-up companies working in the animal health area. In addition, we compete with numerous other producers of animal health products throughout the world.

~~Productivity~~

Our results during the periods presented have benefited from operational and productivity initiatives implemented following recent acquisitions and in response to changing market demand for antibiotics and other headwinds.

Our acquisitions in the six years prior to the acquisition of Bayer Animal Health added, in the aggregate, $1.4 billion in revenue, 4,600 full-time employees and 12 manufacturing and eight R&D sites. The acquisitions of Bayer Animal Health on August 1, 2020 and KindredBio on August 27, 2021 added 3,950 full-time employees, 10 manufacturing sites and five R&D sites (before company-wide restructuring activities initiated in 2020 and 2021). In addition, from 2015 to 2022, changing market demand for antibiotics and other headwinds, such as competition with generics and innovation, affected some of our highest gross margin products, resulting in a change to our product mix and driving operating margin lower. In response, we implemented a number of initiatives across the manufacturing, R&D and marketing, selling and administrative functions. Our manufacturing cost savings strategies included improving manufacturing processes and headcount through lean manufacturing (minimizing waste while maintaining productivity), closing and selling manufacturing sites, consolidating our CMO network, strategically insourcing certain projects and pursuing cost savings opportunities through alternate sources of supply. Additional cost savings have resulted from reducing the number of R&D sites, sales force consolidation and reducing discretionary and other general and administrative operating expenses.


			~~2023 Q1 Form 10-Q \|~~ 27

~~Table of Contents~~

~~Seasonality~~

While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. For example, based upon historical results, approximately 75% and 60% of total annual revenue contributed by our higher-margin parasiticide products ~~Seresto~~ ~~and~~ ~~Advantage Family~~, respectively, has occurred during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere. Therefore, a period-to-period comparison of our historical results may not be meaningful and fluctuations in total revenue for our pet health products are not necessarily an indication of future performance.

~~Foreign Exchange Rates~~

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 90 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. During the three months ended March 31, 2023 and 2022, approximately 53% and 54%, respectively, of our revenue was denominated in foreign currencies. As we operate in multiple foreign currencies, including the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, Chinese yuan and other currencies, changes in those currencies relative to the U.S. dollar impact our revenue, cost of sales and expenses, and consequently, net income. These fluctuations may also affect the ability to buy and sell our products between markets impacted by significant exchange rate variances. Currency movements decreased revenue by 3% during the three months ended March 31, 2023 and 2022.

~~Results of Operations~~

~~The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Revenue $ 1,257 $ 1,226 3 %
Costs, expenses and other:
Cost of sales 494 509 (3) %
% of revenue 39 % 42 % (3) %
Research and development 81 81 — %
% of revenue 6 % 7 % (1) %
Marketing, selling and administrative 327 323 1 %
% of revenue 26 % 26 % — %
Amortization of intangible assets 134 137 (2) %
% of revenue 11 % 11 % — %
Asset impairment, restructuring and other special charges 40 40 — %
Interest expense, net of capitalized interest 64 52 23 %
Other expense, net 9 9 — %
Income before income taxes 108 75 44 %
% of revenue 9 % 6 % 3 %
Income tax expense 5 24 (79) %
Net income $ 103 $ 51 102 %

~~Certain amounts and percentages may reflect rounding adjustments.~~


			~~2023 Q1 Form 10-Q \|~~ 28

~~Table of Contents~~

~~Disaggregated Revenue~~

~~On a global basis, our revenue by product category for the three months ended March 31, 2023 and 2022 is summarized as follows:~~


																	Six Months Ended June 30,
		Revenue				% of Total Revenue				Increase (Decrease)							Revenue				% of Total Revenue				Increase (Decrease)
(Dollars in millions)	(Dollars in millions)	2023		2022		2023		2022		$ Change		% Change		CER (1)		(Dollars in millions)	2023		2022		2023		2022		$ Change		% Change		CC (1)
Pet Health	Pet Health	$	675	$	640	54	%	52	%	$	35	5	%	8	%	Pet Health	$	1,193	$	1,250	52	%	52	%	$	(57)	(5)	%	(3)	%
Farm Animal	Farm Animal	573		569		46	%	46	%	4		1	%	5	%	Farm Animal	1,100		1,122		48	%	47	%	(22)		(2)	%	1	%
Subtotal	Subtotal	1,248		1,209		99	%	99	%	39		3	%	7	%	Subtotal	2,293		2,372		99	%	99	%	(79)		(3)	%	(1)	%
Contract Manufacturing (2)	Contract Manufacturing (2)	9		17		1	%	1	%	(8)		(47)	%	(41)	%	Contract Manufacturing (2)	21		29		1	%	1	%	(8)		(28)	%	(23)	%
Total	Total	$	1,257	$	1,226	100	%	100	%	31		3	%	6	%	Total	$	2,314	$	2,401	100	%	100	%	(87)		(4)	%	(1)	%

Note: Numbers may not add due to rounding

(1)Constant ~~exchange rate (CER)~~Currency (CC), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign ~~exchange.~~exchange rates. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.

(2)Represents revenue from arrangements in which we manufacture products on behalf of a third party.

~~On a global basis, the effect~~The effects of price, foreign exchange rates and volume on changes in revenue for the three and six months ended ~~March 31,~~June 30, 2023 ~~and 2022 was~~were as follows:


Three months ended June 30, 2023 (Dollars in millions)	Revenue		Price	FX Rate	Volume	Total	CC
Pet Health	$	518	4%	(1)%	(19)%	(15)%	(14)%
Farm Animal	527		3%	(2)%	(6)%	(5)%	(3)%
Subtotal	1,045		4%	(1)%	(12)%	(10)%	(9)%
Contract Manufacturing	12		—%	—%	1%	—%	1%
Total	$	1,057	4%	(1)%	(12)%	(10)%	(9)%


Three months ended March 31, 2023 (Dollars in millions)		Revenue		Price	FX Rate	Volume	Total	CER
Six months ended June 30, 2023 (Dollars in millions)									Six months ended June 30, 2023 (Dollars in millions)	Revenue		Price	FX Rate	Volume	Total	CC
Pet Health	Pet Health	$	675	5%	(3)%	3%	5%	8%	Pet Health	$	1,193	5%	(2)%	(7)%	(5)%	(3)%
Farm Animal	Farm Animal	573		5%	(4)%	—%	1%	5%	Farm Animal	1,100		4%	(3)%	(3)%	(2)%	1%
Subtotal	Subtotal	1,248		5%	(3)%	2%	3%	7%	Subtotal	2,293		4%	(2)%	(5)%	(3)%	(1)%
Contract Manufacturing	Contract Manufacturing	9		—%	(7)%	(41)%	(47)%	(41)%	Contract Manufacturing	21		—%	(4)%	(23)%	(28)%	(23)%
Total	Total	$	1,257	5%	(3)%	1%	3%	6%	Total	$	2,314	4%	(2)%	(5)%	(4)%	(1)%

Three months ended March 31, 2022
(Dollars in millions)

Revenue Price FX Rate Volume Total CER
Pet Health $ 640 2% (3)% —% (1)% 2%
Farm Animal 569 1% (3)% —% (2)% 1%
Subtotal 1,209 2% (3)% —% (1)% 2%
Contract Manufacturing 17 —% (3)% (8)% (11)% (8)%
Total $ 1,226 2% (3)% —% (1)% 2%

Note: Numbers may not add due to rounding

~~Revenue~~

Pet Health revenue ~~increased $35~~decreased $92 million, or 5%15%, for the three months ended ~~March 31,~~June 30, 2023, compared to the similar period in 2022, driven by ~~increases in price~~lower volumes and ~~volume, partially offset~~to a lesser extent, by an unfavorable impact from foreign exchange ~~rates. Revenue~~rates, partially offset by increased ~~an estimated $65 million to $80 million over prior year due~~pricing. For the three months ended June 30, 2023, lower volumes principally related to the ~~modification~~impact of the ERP system integration commercial blackout periods, which we believe resulted in modifications of certain customers' purchasing habits of legacy Bayer Animal Health products, ~~in anticipation of our ERP system integration. Excluding the impact of this shift~~shifting an estimated $65 million to $80 million in revenue from the second quarter of 2023 to the first quarter of 2023. Additionally, sales volumes were negatively impacted by declines in demand for retail parasiticide products in Spain and continued competitive pressure on certain parasiticide products in the U.S., partially offset by higher demand for pain and OTC products in the U.S. and revenue from new products.

Pet Health revenue decreased $57 million, or 5%, for the six months ended June 30, 2023, compared to the similar period in 2022, driven by lower volumes and to a ~~constant currency basis,~~lesser extent, by an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the ~~decrease~~six months ended June 30, 2023, lower volumes were attributable to pressured market demand for retail parasiticide products in several international markets, competitive pressure on certain U.S. prescription products and the impact of supply disruption in vaccines in the U.S. These reductions in sales volumes were partially offset by higher demand for pain and OTC products in the U.S. and increased revenue ~~was primarily attributable~~from new products.

Farm Animal revenue decreased by $26 million, or 5%, for the three months ended June 30, 2023, compared to the similar period in 2022, driven by lower volumes and an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the three months ended June 30, 2023, lower volumes principally related to the impact of ~~a supply disruption~~the ERP system integration commercial blackout periods, which we believe resulted in ~~vaccines, a decline in sales~~modifications of certain ~~parasiticide~~customers' purchasing habits of legacy Bayer Animal Health products, shifting an estimated $25 million to $30 million in revenue from the second quarter of 2023 to the first quarter of 2023. Additional revenue from new


			2023 Q2 Form 10-Q \| 23

Ta le of Contents

products, led by Experior, strength in European poultry and ~~declines~~increased aqua demand were mostly offset by supply constraints for cattle vaccines in ~~retail products primarily~~the U.S. and a weaker sheep season.

Farm Animal revenue decreased $22 million, or 2%, for the six months ended June 30, 2023, compared to the similar period in ~~Europe,~~2022, driven by lower volumes and an unfavorable impact from foreign exchange rates, partially offset by increased pricing. For the six months ended June 30, 2023, lower volumes were attributable to supply disruptions in U.S. cattle vaccines, reduced sales of cattle implants due to U.S. regulatory changes and generic competition. These reductions in volumes were partially offset by increased poultry demand outside of the U.S. and for aqua, and increased revenue from new products, led by Experior.

Cost of Sales


	Three Months Ended June 30,								Six Months Ended June 30,
(Dollars in millions)	2023			2022			% Change		2023			2022			% Change
Cost of sales	$	434		$	484		(10)	%	$	928		$	993		(7)	%
% of revenue	41		%	41		%			40		%	41		%

Cost of sales decreased $50 million for the three months ended June 30, 2023, primarily due to lower revenue compared to the same period in the prior year, while cost of sales as a percentage of revenue was flat year over year. Product price increases and ~~innovation revenue.~~the impact of foreign exchange rates on international inventories sold were largely offset by inflationary impacts on input costs and conversion costs, lower manufacturing productivity and the impact of certain customers' elevated purchasing of legacy Bayer Animal Health products in the first quarter of 2023, ahead of our ERP system integration, as this latter event had a larger impact on our Pet Health products, which typically have higher gross margins.

Cost of sales decreased $65 million for the six months ended June 30, 2023, primarily due to lower revenue compared to the same period in the prior year. Cost of sales as a percentage of revenue decreased from 41% for the six months ended June 30, 2022 to 40% for the six months ended June 30, 2023, due to a combination of product price increases and the impact of foreign exchange rates on international inventories sold, partially offset by inflationary impacts on input costs and conversion costs and lower manufacturing productivity.

Research and Development


	Three Months Ended June 30,								Six Months Ended June 30,
(Dollars in millions)	2023			2022			% Change		2023			2022			% Change
Research and development	$	81		$	82		(1)	%	$	162		$	163		(1)	%
% of revenue	8		%	7		%			7		%	7		%

Research and development expenses were essentially flat for the three and six months ended June 30, 2023, as compared to the same periods in the prior year.

Marketing, Selling and Administrative


	Three Months Ended June 30,								Six Months Ended June 30,
(Dollars in millions)	2023			2022			% Change		2023			2022			% Change
Marketing, selling and administrative	$	353		$	343		3	%	$	680		$	666		2	%
% of revenue	33		%	29		%			29		%	28		%

Marketing, selling and administrative expenses increased $10 million and $14 million for the three and six months ended June 30, 2023, respectively, compared to the same periods in the prior year, primarily driven by increases in marketing spend, employee compensation costs, travel and meeting expenses and consulting services.

Amortization of Intangible Assets


	Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions)	2023		2022		% Change		2023		2022		% Change
Amortization of intangible assets	$	136	$	133	2	%	$	270	$	270	—	%

Amortization of intangible assets was essentially flat for the three and six months ended June 30, 2023, respectively, compared to the same periods in the prior year, as the addition of amortization of intangible assets recorded from the acquisition of certain assets of NutriQuest during the current year was mostly offset by the impact of foreign exchange rates.


			2023 Q1Q2 Form 10-Q \| 2924

~~Table~~Ta le of Contents

~~Farm~~Asset Impairment, Restructuring and Other Special Charges


	Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions)	2023		2022		% Change		2023		2022		% Change
Asset impairment, restructuring and other special charges	$	35	$	86	(59)	%	$	75	$	126	(40)	%

For additional information regarding our asset impairment, restructuring and other special charges, see Note 5. Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements. The decrease of $51 million for both the three and six months ended June 30, 2023, compared to the prior year, was primarily due to the $59 million charge related to the expensing of an IPR&D asset licensed from BexCaFe during the three months ended June 30, 2022, which did not recur in the current year. Amounts recorded during the three and six months ended June 30, 2023 primarily represented costs associated with the implementation of new systems, programs and processes resulting from the integration of Bayer Animal ~~revenue~~Health.

Interest Expense, Net of Capitalized Interest


	Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions)	2023		2022		% Change		2023		2022		% Change
Interest expense, net of capitalized interest	$	74	$	67	10	%	$	138	$	119	16	%

Interest expense, net of capitalized interest increased $7 million and $19 million for the three and six months ended June 30, 2023, respectively, compared to the same periods in the prior year, primarily due to higher interest rates on our outstanding variable-rate debt and rate increases on our Senior Notes driven by $4credit downgrades. The increases were partially offset by a $17 million ~~or 1%~~debt extinguishment charge recorded during the three months ended June 30, 2022, which did not recur in the current year.

Other expense (income), net


	Three Months Ended June 30,					Six Months Ended June 30,
(Dollars in millions)	2023		2022		% Change	2023		2022		% Change
Other expense (income), net	$	23	$	(6)	NM	$	32	$	3	NM

Other expense (income), net for the three months ended ~~March 31,~~June 30, 2023, ~~driven by an increase~~primarily consisted of a settlement provision of $15 million recorded in ~~price, partially offset by an unfavorable impact from foreign exchange rates. Revenue increased an estimated $25 million to $30 million over prior year due~~June related to the ~~modification~~Seresto class action lawsuits (see Note 12. Commitments and Contingencies for further information). Devaluation losses of ~~certain customers' purchasing habits of legacy Bayer Animal Health products in anticipation of our ERP system integration. Excluding the impact of this shift in revenue from the second quarter~~approximately $7 million related to the ~~first quarter~~hyperinflationary environment in Turkey and on a constant currency basis, the year over year change was primarily attributable to increased demand in Europe and Asia, primarily in poultry, innovation revenue and price increases, offset by a decrease in demand for poultry products in the U.S.Argentina were also recorded within other expense (income), ~~generic competition, timing of aqua purchases in the prior year and supply disruptions of cattle vaccines in the U.S.~~

~~Cost of Sales~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Cost of sales $ 494 $ 509 (3) %
% of revenue 39 % 42 %

~~Cost of sales as a percentage of revenue decreased for~~net during the three months ended ~~March 31,~~June 30, 2023 primarily due to due to the modification of certain customers' purchasing habits of legacy Bayer Animal Health products in anticipation of our ERP system integration, which primarily related to Pet Health products which have higher margins, as well as product price increases and improvements in manufacturing productivity, partially offset by inflationary impacts on input costs and conversion costs.

~~Research and Development~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Research and development $ 81 $ 81 — %
% of revenue 6 % 7 %

~~R&D expenses were flat~~($9 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023). Other expense (income), net for the six months ended June 30, 2023, also included foreign exchange losses and ~~decreased slightly as a percentage of revenue.~~

mark-to-market adjustments on equity investments.

~~Marketing, Selling and Administrativ~~eIncome tax expense (benefit)

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Marketing, selling and administrative $ 327 $ 323 1 %
% of revenue 26 % 26 %


	Three Months Ended June 30,							Six Months Ended June 30,
(Dollars in millions)	2023			2022			% Change	2023			2022			% Change
Income tax expense (benefit)	$	18		$	(4)		NM	$	23		$	20		NM
Effective tax rate	(23.0)		%	28.6		%		79.9		%	32.3		%

~~Marketing, selling and administrative expenses~~Income tax expense increased $4to $18 million for the three months ended ~~March 31,~~June 30, 2023, ~~primarily driven by increases~~compared to an income tax benefit of $4 million in ~~employee compensation costs, travel and meeting expenses and spend related to consulting services, partially offset by~~ the ~~impact~~same period of ~~foreign exchange rates.~~

~~Amortization of Intangible Assets~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Amortization of intangible assets $ 134 $ 137 (2) %

~~Amortization of intangible assets decreased $3 million~~the prior year. The effective tax rate was negative for the three months ended ~~March 31,~~June 30, 2023, and differed from the statutory income tax rate primarily due to the ~~impact~~earnings mix of income in jurisdictions with statutory tax rates higher than the U.S. and losses in the U.S. and various foreign ~~exchange~~affiliates for which there was no tax benefit, as valuation allowances have been established in those jurisdictions. The income tax benefit for the three months ended June 30, 2022, was primarily attributable to a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates ~~partially offset by the addition of amortization of intangible assets recorded from the acquisition of certain assets of NutriQuest~~swaps during the ~~period.~~three months ended June 30, 2022.

Income tax expense increased $3 million for the six months ended June 30, 2023, compared to the same period in the prior year, and the effective tax rate increased to 79.9%, compared to 32.3% in the prior year period. These increases were primarily due to changes in the earnings mix between periods resulting in projected losses in the U.S. and various other foreign affiliates for which there was no tax benefit, as valuation allowances had been established in those jurisdictions. Income tax expense for the six months ended June 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps during the three months ended June 30, 2022.


			2023 Q1Q2 Form 10-Q \| 3025

~~Table~~Ta le of Contents

~~Asset Impairment, Restructuring and Other Special Charges~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Asset impairment, restructuring and other special charges $ 40 $ 40 — %

For additional information regarding our asset impairment, restructuring and other special charges, see Note 6: Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.

Asset impairment, restructuring and other special charges were flat in the three months ended March 31, 2023 as compared to the prior year. Amounts recorded during the three months ended March 31, 2023 primarily represented costs associated with the implementation of new systems, programs, and processes due to the integration of Bayer Animal Health.

~~Interest Expense, Net of Capitalized Interest~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Interest expense, net of capitalized interest $ 64 $ 52 23 %

~~Interest expense, net of capitalized interest increased $12 million for the three months ended March 31, 2023, primarily due to higher interest on variable-rate debt due to rate increases.~~

~~Other Expense, Net~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Other expense, net $ 9 $ 9 — %

Other expense recorded during the three months ended March 31, 2023 primarily consisted of foreign exchange losses and mark-to-market adjustments on equity investments, partially offset by certain components of net periodic benefit cost, a gain recorded in connection with the sale of additional equity by BiomEdit, and milestones earned and equity issued to us in relation to a license agreement. Other expense recorded during the three months ended March 31, 2022 primarily consisted of mark-to-market adjustments on equity investments and foreign exchange losses, partially offset by certain components of net periodic benefit cost.

~~Income Tax Expense~~

Three Months Ended March 31,
(Dollars in millions) 2023 2022 % Change
Income tax expense $ 5 $ 24 (79) %
Effective tax rate 4.4 % 31.6 %

Income tax expense decreased $19 million for the three months ended March 31, 2023. The effective tax rate decreased for the three months ended March 31, 2023 as compared to the prior year and differs from the statutory income tax rate largely due to jurisdictional earnings mix of projected income in lower tax jurisdictions, partially offset by losses in the U.S. and a Southeast Asia affiliate, for which there is no tax benefit as valuation allowances have been established in those countries, and refinements in the calculation of required capitalization of certain R&D expenses. See Note 11: Income Taxes to the condensed consolidated financial statements.


			~~2023 Q1 Form 10-Q \|~~ 31

~~Table of Contents~~

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, ~~following U.S. tax reforms,~~ the income taxes associated with transferring cash to the U.S. We intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our business evolves, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.

We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations, ~~which include~~such as principal and interest payments, as well as interest rate swaps, operating lease payments, purchase obligations and costs associated with ~~the integrations~~business integrations. As of ~~Bayer Animal Health.~~June 30, 2023, we had cash and cash equivalents of $367 million and unused borrowing capacity on our Revolving Credit Facility of approximately $500 million. In addition, we have the ability to access capital markets to obtain debt ~~refinancing~~financing for longer-term funding, if ~~required, to service our long-term debt obligations.~~required. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.

Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As ~~markets~~market conditions change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful" in Part I of our 2022 Form 10-K.

Cash Flows

The following table provides a summary of cash flows from operating, investing and financing activities for the ~~periods presented:~~six months ended June 30, 2023 and 2022:

(Dollars in millions) Three Months Ended March 31,
Net cash provided by (used for): 2023 2022 $ Change
Operating activities $ (145) $ (62) $ (83)
Investing activities (55) (29) (26)
Financing activities 174 (200) 374
Effect of exchange-rate changes on cash and cash equivalents (1) (5) 4
Net decrease in cash and cash equivalents $ (27) $ (296) $ 269


(Dollars in millions)	Six Months Ended June 30,
Net cash (used for) provided by:	2023		2022		$ Change
Operating activities	$	(84)	$	250	$	(334)
Investing activities	(98)		(66)		(32)
Financing activities	213		(296)		509
Effect of exchange-rate changes on cash and cash equivalents	(9)		(19)		10
Net increase (decrease) in cash and cash equivalents	$	22	$	(131)	$	153

Operating activities

Cash used for (provided by) operating activities ~~increased $83~~decreased $334 million to ~~$145~~a use of cash of $84 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023, ~~from $62~~compared to cash provided by operating activities of $250 million for the ~~three~~six months ended ~~March 31, 2022, primarily due to a~~June 30, 2022. The decrease in cash ~~resulting~~ from operating activities primarily relates to changes in operating assets and liabilities, particularly accounts receivable and ~~inventories.~~

inventories, as well as $132 million of proceeds from interest rate swap settlements that were received during the six months ended June 30, 2022, that did not recur in the current year.

In the past, we have extended our payment terms for distributors on occasion. Specifically, due to the ERP system integration ~~scheduled to be~~ completed in the second quarter of 2023, we increased inventories on hand and extended payment terms on sales totaling $35 million for some customers during the first quarter of 2023 to ensure that our product was available for a period of time during which there were no shipments. Although we presently have no plans to do so in the future, it is ~~also~~ possible that we will need to extend payment terms in certain situations, for example, as a result of ~~the COVID-19 global health pandemic,~~ competitive pressures, macroeconomic factors and the need for certain inventory levels in our distribution channels to avoid supply disruptions. ~~If so,~~In the event we do extend payment terms in the future, such extensions ~~of customer payment terms~~ could result in additional uses of ~~our~~cash.

Investing activities

Cash used for investing activities was $98 million for the six months ended June 30, 2023 as compared to $66 million for the six months ended June 30, 2022. The increase in cash ~~flow.~~

used for investing activities was primarily driven by cash paid for the acquisition of certain assets of NutriQuest of $16 million during the six months ended June 30, 2023 as well as a year over year increase in cash paid for intangible assets, primarily related to


			2023 Q1Q2 Form 10-Q \| 3226

~~Table~~Ta le of Contents

~~Investing activities~~

~~Cash used~~development/regulatory milestones achieved upon FDA approval of the original new animal drug application for ~~investing activities was $55 million~~Bexacat in December 2022 (see Note 4. Acquisitions, Divestitures and Other Arrangements for the three months ended March 31, 2023 as compared to $29 million for the three months ended March 31, 2022. The increase was primarily driven by cash paid for the acquisition of certain assets of NutriQuest during the three months ended March 31, 2023 as well as a year over year increase in cash paid for intangible assets, partially offset by a year over year decrease in cash used for purchases of software.

further information).

Financing activities

Cash provided by financing activities was ~~$174~~$213 million for the ~~three~~six months ended ~~March 31,~~June 30, 2023 as compared to cash used for financing activities of ~~$200~~$296 million for the ~~three~~six months ended ~~March 31,~~June 30, 2022. Cash provided by financing activities during the ~~three~~six months ended ~~March 31,~~June 30, 2023, ~~primarily~~ reflected proceeds of $250 million from our revolving credit facility, partially offset by the repayment of indebtedness outstanding under our long-term borrowings. Cash used for financing activities of $296 million during the ~~three~~six months ended ~~March 31,~~June 30, 2022, primarily reflected the tender offer completed during the period as well as net repayments on our revolving credit facility and the repayment of indebtedness outstanding under our ~~Term Loan~~term loan B credit facility, ~~and net repayments on~~partially offset by proceeds from the issuance of our ~~revolving credit facility.~~

incremental term facilities.

Description of Indebtedness

For a complete description of our existing debt and available credit facilities as of ~~March 31,~~June 30, 2023 and December 31, 2022, see Note ~~10:~~10. Debt within Item 8, “Financial Statements and Supplementary Data,” of Part II of our 2022 Form 10-K. New developments are discussed in Note 9:8. Debt of this Form 10-Q.

~~Contractual Obligations~~

Our contractual obligations and commitments as of March 31, 2023 are primarily comprised of long-term debt obligations, operating leases and purchase obligations. Our long-term debt obligations are comprised of our expected principal and interest obligations. Purchase obligations consist of open purchase orders as of March 31, 2023 and contractual payment obligations with significant vendors which are noncancelable and are not contingent. These obligations are primarily short-term in nature. See Note 12: Commitments and Contingencies to the condensed consolidated financial statements for further discussion regarding the contractual obligations related to our new corporate headquarters in Indianapolis, Indiana.

Critical Accounting Policies and Estimates

The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, ~~by us,~~ often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our 2022 Form 10-K. There ~~have been~~were no significant changes or developments in the application of our critical accounting policies during the ~~three~~six months ended ~~March 31,~~June 30, 2023.

Goodwill Impairment Testing

We evaluate goodwill for impairment on an annual basis and when certain qualitative impairment indicators are present that would more likely than not reduce the fair value of our single reporting unit below its carrying amount.

In the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a goodwill impairment review. Based on our qualitative assessment, we concluded that it was more likely than not that the fair value of our single reporting unit was less than its carrying value, and therefore, we were required to perform a quantitative goodwill impairment test, which involved comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimated the fair value of our single reporting unit using a combination of the income and market approach.


			~~2023 Q1 Form 10-Q \|~~ 33

~~Table of Contents~~

Significant management judgment is required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that are used in the discounted cash flow method of valuation. These include, but are not limited to, estimates and assumptions regarding (1) our future cash flows, revenue, and other profitability measures, (2) the long-term growth rate of our business, and (3) the determination of our weighted-average cost of capital, which is a factor in determining the discount rate. We make these judgments based on our historical experience, relevant market size, historical pricing of similar products and expected industry trends. These assumptions are subject to change in future periods because of, among other things, additional information, financial information based on further historical experience, changes in competition, our investment decisions, volatility in foreign currency exchange rates, results of research and development and changes in macroeconomic conditions, including rising interest rates and inflation. A change in these assumptions or the use of alternative estimates and assumptions could have a significant impact on the estimated fair value and may expose us to goodwill impairment losses.

As a result of our quantitative assessment, we estimated that the fair value of our single reporting unit exceeded the carrying amount by more than 20% as of September 30, 2022 and, therefore, no impairment existed with respect to our goodwill. Given ~~the further decline in~~ our market capitalization ~~relative to~~remained lower than our book value as of June 30, 2023, we reevaluated our impairment testing from a qualitative perspective as of ~~March 31, 2023. There was~~this date, with no change to our previous conclusion that no impairment ~~exists, primarily due to decreases in interest rates impacting our cost of capital and improvements in certain drivers of our fair value.~~exists.


			2023 Q2 Form 10-Q \| 27

Ta le of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Exchange Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.

We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates in future periods.

We estimate that a hypothetical 10% adverse movement in all foreign currency exchange rates related to the translation of the results of our foreign operations would decrease our net income by approximately $7 million for the three months ended March 31, 2023.

We generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. We have concluded that our Argentina subsidiary is operating in a hyperinflationary market. As a result, beginning in the second quarter of 2018, the functional currency of our Argentina subsidiary changed from the local currency to the U.S. dollar. During the ~~three~~six months ended ~~March 31,~~June 30, 2023, revenue in Argentina represented less than 1% of our consolidated revenue. Assets held in Argentina as of ~~March 31,~~June 30, 2023 represented less than 1% of our consolidated assets.

During the first quarter of 2022, Turkey’s three-year cumulative inflation rate also exceeded 100%, and as such, we concluded that Turkey became a hyperinflationary economy for accounting purposes. As of April 1, 2022, we applied hyperinflationary accounting for our subsidiary in Turkey and changed its functional currency from the Turkish lira to the U.S. dollar. During the ~~three~~six months ended ~~March 31,~~June 30, 2023, revenue in Turkey represented less than 1% of our consolidated revenue. Assets held in Turkey as of ~~March 31,~~June 30, 2023 represented less than 1% of our consolidated assets.

~~While the~~The application of hyperinflationary ~~conditions did not~~accounting for our subsidiaries in Argentina and Turkey have ~~a material impact on our business~~resulted in approximately $9 million of foreign currency related expense during the ~~three~~six months ended ~~March 31,~~June 30, 2023, inwhich was included within other expense (income), net. In the future, we may incur larger currency devaluations, which could have a material adverse impact on our results of operations.


			~~2023 Q1 Form 10-Q \|~~ 34

~~Table of Contents~~

Interest Risk

During the first quarter of 2023, our variable-rate debt was subject to fluctuations in interest rates based on both LIBOR and Term SOFR. ~~However, effective~~Effective April 1, 2023, we transitioned the reference rate used in our credit facilities, and as a result, our variable-rate debt is now exclusively indexed to Term ~~SOFR.~~SOFR, including the new Securitization Facility entered into on August 3, 2023 (see Note 8. Debt for further details). As of ~~March 31,~~June 30, 2023, we held ~~certain~~ interest rate swap agreements with a notional value of ~~$3,050~~$3,800 million that ~~have~~had the economic effect of modifying this amount of our ~~variable interest such that a portion~~variable-rate debt to fixed-rate. Subsequent to the issuance of the ~~variable-rate interest payable becomes fixed. As~~Securitization Facility and early redemption of ~~March 31,~~the 4.272% Senior Notes due 2023, ~~$4,144 million and $1,936 million~~approximately 75% of our ~~total~~ long-term ~~debt, including the current portion, is~~indebtedness now bears interest at a fixed-rate ~~debt~~ (including variable-rate converted to fixed-rate through the use of interest rate swaps) and unhedged variable-rate debt, respectively. During the three months ended March 31, 2023, we recorded a loss of $48 million, net of taxes on these interest rate swaps in other comprehensive income. See Note 10: Financial Instruments and Fair Value to the condensed consolidated financial statements for further information..

ITEM 4. CONTROLS AND PROCEDURES

(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized and reported on a timely basis.

Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of ~~March 31,~~June 30, 2023. As disclosed in Item 9A of Part II of our 2022 Form 10-K, management concluded that a material weakness existed as of December 31, 2022 resulting from the ineffective review of the annual income tax provision, including the valuation allowance related to deferred tax assets. We ~~are in the process of identifying all issues contributing to the material weakness and developing~~have developed a remediation ~~plan. The implementation of this remediation~~ plan ~~will require, at a minimum,~~which requires the effective operation of certain quarterly and annual controls. Therefore, the material weakness cannot be fully remediated until we assess the effectiveness of our internal control over financial reporting for the year ending December 31, 2023. Based on this evaluation, the chief executive officer and the chief financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures remained ineffective.

(b)Changes in Internal Controls. During the ~~first~~second quarter of 2023, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than the aforementioned material weakness.


			2023 Q1Q2 Form 10-Q \| 3528

~~Table~~Ta le of Contents

PART II

ITEM 1. LEGAL PROCEEDINGS

See Note ~~12:~~12. Commitments and Contingencies to the condensed consolidated financial statements for a summary of our legal proceedings, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Our risk factors are documented in Item 1A of Part I of our 2022 Form 10-K, which is incorporated herein by reference. Other than the revisions set forth below, there have been no material changes from the risk factors previously disclosed in the 2022 Form 10-K.

The following risk factors have been changed from the risk factors that were previously disclosed:

Unanticipated safety, quality or efficacy concerns or identified concerns associated with our products may harm our reputation and have an adverse impact on our performance.

Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not scientifically or clinically supported, potentially leading to product recalls, withdrawals or suspended or reduced sales, as well as product liability and other claims. Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a product’s sales.

For example, lawsuits seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been filed against us arising out of the use of Seresto, a non-prescription flea and tick collar for cats and dogs, based on media reports alleging that the collar has caused injury and death to pets. Further, in 2021, the U.S. House of Representatives' then-subcommittee chair requested that we produce certain documents and information related to the Seresto collar, made a request to temporarily remove Seresto collars from the market and, during a hearing at which our President and Chief Executive Officer (CEO) testified, again called for removal of the collars from the market. ~~We do not anticipate~~

Since that ~~the collars will be removed from the market by~~time, on July 13, 2023, the EPA ~~or any other regulatory agencies or that any potential or agreed upon brand stewardship actions will have meaningful commercial impact on~~announced the completion of its comprehensive, multi-year review of the Seresto ~~brand.~~flea and tick collar and confirmed the continued registration of the collar. However, if any similar claims with respect to our other products are resolved adversely to us, or if a regulatory agency determines that a recall or cancellation of registrations of any of our products is necessary, such action could cause harm to our reputation, reduce our product sales, result in monetary penalties and other costly remedies against us, and could therefore have a material adverse effect on our business, financial condition and results of operations.

In addition, we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products in general, by food producers, veterinarians and pet owners. Any concern as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns, including those relating to Seresto, and the related harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of whether such reports are accurate.


			~~2023 Q1 Form 10-Q \|~~ 36

~~Table of Contents~~

Changes in our credit rating could increase our interest expense and restrict our access to, and negatively impact the terms of, current or future financings or trade credit.

Credit rating agencies continually revise their ratings for the companies that they follow, including us. Credit rating agencies also evaluate our industry as a whole and may change their credit ratings for us based on their overall view of our industry. We cannot be sure that credit rating agencies will maintain their ratings on us and certain of our debt. The acquisition of Bayer Animal Health had a negative impact on our credit ratings, leading to higher borrowing expenses. Additionally, S&P, Moody's and Fitch downgraded our credit ratings in February, March and April 2023, respectively. Because the ratings of certain of our senior unsecured notes have been downgraded, we are required to pay additional interest under the senior unsecured notes. Any further downgrades could result in requirements to pay additional interest under the senior unsecured notes. Moreover, any decision to downgrade our ratings could restrict our access to, and negatively impact the terms of, current or future financings and trade credit extended by our suppliers of raw materials or other vendors.

Changes in interest rates may adversely affect our earnings and/or cash flows.

During the first quarter of 2023, certain of our credit facilities bore interest at variable interest rates that used the London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. Effective April 1, 2023, and in accordance with the


			2023 Q2 Form 10-Q \| 29

Ta le of Contents

provisions outlined in our underlying credit agreements, we transitioned the reference rate used in our credit facilities from LIBOR to Term SOFR.

Term SOFR measures the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. While this change did not have a material impact on our condensed consolidated financial statements, we continue to be exposed to the risk of rising interest rates, given our level of variable-rate indebtedness. Term SOFR rate increases over the course of 2023 have led to an increase in both our interest expense and cash paid for interest, and any further increases in Term SOFR rates would expose us to additional interest rate risk and additional expense. Further, we are exposed to the risk of rising interest rates to the extent we fund our operations with short-term or variable-rate borrowings.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(none)

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

(none)

ITEM 4. MINE SAFETY DISCLOSURES

(none)

ITEM 5. OTHER INFORMATION

~~(none)~~During the three months ended June 30, 2023, no director or officer of the Company adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.


			2023 Q1Q2 Form 10-Q \| 3730

~~Table~~Ta le of Contents

ITEM 6. EXHIBITS

The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.



			Exhibit Number						Description












			10.1						A mended and Restated Elanco Animal Health Incorporated E mplo y ee Stock Purchase Plan (incorporated by reference to Appendix B to the Definitive Proxy Statement for the 2023 Annual Meeting of Shareholders filed with the SEC on April 6, 2023).
			10.2						Amended and Restated 2018 Elanco Animal Health Incorporated Stock Plan (incorporated by reference to Appendix C to the Definitive Proxy Statement for the 2023 Annual Meeting of Shareholders filed with the SEC on April 6, 2023).
			10.3						Receivables Loan Agreement among Elanco SPEAR LLC, Elanco US Inc., The Various Lenders and Lender Agents from Time to Time Party Thereto and Coöperatieve Rabobank U.A., New York Branch, dated as of August 3, 2023 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 7, 2023).























			31.1						Section 302 Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

			31.2						Section 302 Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

			32						Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

			101						Interactive Data Files.
			104						Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101).


			2023 Q1Q2 Form 10-Q \| 3831

~~Table~~Ta le of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		ELANCO ANIMAL HEALTH INCORPORATED
		(Registrant)

Date:	~~May 9,~~August 7, 2023	/s/ Jeffrey N. Simmons
		Jeffrey N. Simmons
		President and Chief Executive Officer
		(Principal Executive Officer)

Date:	~~May 9,~~August 7, 2023	/s/ Todd S. Young
		Todd S. Young
		Executive Vice President, Chief Financial Officer
		(Principal Financial Officer)


			2023 Q1Q2 Form 10-Q \| 3932


(Dollars in millions)	Three Months Ended March 31,
Net cash provided by (used for):	2023		2022		$ Change
Operating activities	$	(145)	$	(62)	$	(83)
Investing activities	(55)		(29)		(26)
Financing activities	174		(200)		374
Effect of exchange-rate changes on cash and cash equivalents	(1)		(5)		4
Net decrease in cash and cash equivalents	$	(27)	$	(296)	$	269